The O
MS/MS O
spectrum O
of O
PE B-lipid
(42:4) I-lipid
is O
shown O
in O
the O
, O
which O
showed O
the O
characteristic O
product O
ion O
due O
to O
the O
loss O
of O
141 O
Da O
(ethanolaminephosphate) O
from O
the O
[M+H]_+ O
ion, O
and O
this O
ion O
known O
to O
be O
specific O
for O
PE O
[,]. O

Plasma O
lipids O
specific O
to O
obesity‐related O
insulin O
resistance O
(i.e., O
different O
between O
OIS O
and O
OIR, O
but O
not O
between O
OIR O
and O
Lean) O
included O
DG(14:1_16:0), B-lipid
CE(22:4) B-lipid
and O
PC(O‐35:4) O
(higher) O
and O
Hex2Cer(d18:1/22:0), O
Hex2Cer(d18:1/24:0) O
and O
LPC(22:0) B-lipid
(lower). O

Measurements O
of O
lipids O
composed O
of O
two O
fatty O
acids O
are O
determined O
as O
the O
sum O
of O
the O
carbons O
and O
the O
double O
bonds O
across O
both O
fatty O
acids, O
e.g. O
PC(36:4) B-lipid
based O
on O
previous O
methods O
(Weir O
et O
al. O
; O

According O
to O
univariate O
statistics, O
the O
following O
compounds O
were O
significantly O
different O
between O
samples O
from O
the O
pre-symptomatic O
individuals O
and O
controls: O
oleic O
acid O
(p O
= O
0.040, O
AUROC O
= O
0.67), O
β-hydroxypalmitic O
acid O
(p O
= O
0.049, O
AUROC O
= O
0.67), O
kynurenine O
(p O
= O
0.015, O
AUROC O
= O
0.66), O
hypoxanthine O
(p O
= O
0.044, O
AUROC O
= O
0.69), O
LPC(16:0) B-lipid
(p O
= O
0.049, O
AUROC O
= O
0.69), O
LPC(14:0) B-lipid
(p O
= O
0.012, O
AUROC O
= O
0.70) O
and O
3-indolelactic O
acid O
(p O
= O
0.045, O
AUROC O
= O
0.65). O

This O
analysis O
failed O
to O
discern O
differences O
among O
the O
3 O
groups O
in O
their O
regioisomeric O
composition; O
the O
14,15-EET B-lipid
predominated O
and O
the O
11,12-EET B-lipid
was O
least. O

also O
show O
chromatograms O
of O
the O
second O
mass O
transitions O
of O
m/z O
622 O
to O
282 O
for O
Cer(22:0) B-lipid
and O
m/z O
650 O
to O
282 O
for O
Cer(24:0), B-lipid
respectively, O
that O
were O
used O
for O
purposes O
of O
confirmation. O

Changes O
in O
lactosylceramide O
correlated O
positively O
with O
△ O
decanoylcarnitine O
and O
negatively O
with O
△ O
L-valine, O
△ O
lysoPCs O
(14:0, O
16:0, O
18:2, O
18:0, O
20:3, O
and O
22:6), O
and O
△ O
PC B-lipid
(18:0/20:4) I-lipid
(r O
= O
0.266, O
P O
= O
0.004). O

We O
observed O
here O
SM(36:3) B-lipid
as O
a O
marker O
of O
TFA O
intake. O

A O
discontinuous O
gradient O
was O
generated O
to O
resolve O
the O
analytes O
by O
mixing O
solvent O
A O
(0.1% O
propionic B-lipid
acid I-lipid
in O
water) O
with O
solvent O
B O
(0.1% O
acetic O
acid O
in O
methanol). O

20-HETE B-lipid
producing O
CYP450 O
isoform O
specific O
primer O
sequences O
were O
as O
follows: O
CYP4A11-F O
(ATGAAGTGTGCCTTCAGCCA), O
CYP4A11-R O
(AAG O
GCATTCC O
TCACACGGG), O
CYP4A22-F O
(AATGGGAAGAGCTCCTTGGC), O
CYP4A22-R O
(AAGGCATTCCTCATACAGC), O
CYP4F2-F O
(AAGCA O
CCCAGAATACCAGGA), O
CYP4F2-R O
(TCATGCACA O
TGGTCAG O
GAAG), O
CYP4F3-F(CTGTCGGCAGGAGGTACAAG), O
CYP4F3-R O
(CCTCAGGCTCTCCTTAATGC). O

Regarding O
phosphatidylglycerol O
(PGs), O
which O
a O
phosphoglycerol O
moiety O
occupies O
a O
glycerol O
substitution O
site, O
little O
evidence O
has O
been O
shown O
on O
their O
relationship O
with O
CHD, O
and O
we O
were O
the O
first O
to O
reveal O
a O
positive O
relationship O
between O
PG(20:3/2:0) B-lipid
and O
CHD O
(OR: O
3.938; O
95% O
CI: O
(1.891, O
8.204); O

Of O
the O
nine O
PCs O
associated O
with O
obesity, O
seven O
were O
available O
for O
replication O
and O
five O
(71%), O
including O
PC B-lipid
(38:3), I-lipid
replicated O
(Supplementary O
Table O
2). O

Such O
effective O
mechanism O
might O
results O
in O
the O
activation O
and O
successful O
antioxidative O
response, O
as O
displayed O
by O
the O
decreased O
concentration O
of O
9-HODE, B-lipid
and O
9-oxoODE O
in O
centenarians. O

In O
this O
context O
malondialdehyde, O
4-hydroxynonenal, B-lipid
propanal B-lipid
and O
hexanal B-lipid
have O
been O
described O
as O
suitable O
markers O
[, O
]. O

Low O
and O
high O
energy O
spectra O
for O
coeluting O
TG B-lipid
(52:4) I-lipid
and O
TG B-lipid
(54:5) I-lipid
species, O
displaying O
neutral O
losses O
(NL) O
and O
fragments O
indicative O
of O
fatty O
acyl O
chains O
16:0, O
18:0, O
18:1, O
18:2, O
and O
18:3 O
acyl O
chains. O

To O
analyze O
15-HETE, B-lipid
20 O
HETE, O
11(12)-DiHET O
and O
14(15)-DiHET O
a O
modified O
version O
of O
the O
method O
described O
by O
Mangal O
et O
al. O
was O
used. O

Different O
lyso O
PCs O
in O
addition O
to O
oleamide O
and O
eicosatrienoic B-lipid
acid I-lipid
that O
were O
also O
found O
to O
be O
significant O
in O
our O
study O
have O
been O
previously O
included O
in O
a O
panel O
of O
biomarkers O
for O
differentiating O
early O
stage O
colorectal O
cancer O
patients O
from O
healthy O
controls O
that O
was O
shown O
to O
be O
more O
effective O
than O
the O
carcinoembryonic O
antigen O
biomarker O
usually O
utilised O
in O
diagnosis O
of O
the O
disease. O

A O
redirection O
of O
COX-2 O
metabolism O
toward O
15-HETE B-lipid
and O
its O
anti-inflammatory O
lipoxin O
derivates O
upon O
ASA O
treatment O
has O
been O
demonstrated O
in O
rat O
hepatocytes O
and O
human O
lung O
cancer O
cell O
lines. O

In O
the O
schizophrenia O
cohort, O
significant O
differences O
were O
apparent O
in O
several O
saturated O
FA, O
such O
as O
16:0 O
(palmitic O
acid), O
14:0 O
(myristic O
acid), O
24:0 O
(lignoceric O
acid), O
and O
the O
unsaturated O
essential O
FA B-lipid
18:2 I-lipid
(linoleic O
acid). O

The O
intra-run O
accuracy O
levels O
were O
−3.2–0.0%RE O
and O
−1.0–4.1%RE O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively. O

These O
OzID O
signals O
can O
thus O
be O
used O
to O
assign O
the O
structure O
of O
the O
sphingomyelin O
eluting O
at O
this O
time O
to O
SM O
d18:2(n O
-4)/22:0, O
while O
the O
other O
two O
contributors, O
SM B-lipid
d18:1/22:1 I-lipid
and O
SM B-lipid
d16:1/24:1, I-lipid
can O
be O
excluded O
from O
consideration O
(in O
this O
retention O
time O
slice) O
as O
no O
losses O
characteristic O
of O
the O
expected O
n O
-7 O
or O
n O
-9 O
sites O
of O
unsaturation O
in O
the O
associated O
side O
chains O
were O
observed. O

Identified O
metabolites: O
3, O
alanine; O
6, O
asparagine; O
7, O
aspartic O
acid; O
8, O
betaine; O
9, O
citric O
acid; O
12, O
formic O
acid; O
15, O
glutamic O
acid; O
17, O
glycine; O
20, O
histidine; O
21, O
3-hydroxybutyric O
acid; O
22, O
4-hydroxyproline; O
23, O
2-hydroxyisobutyric O
acid; O
25, O
isoleucine; O
28, O
lactic O
acid; O
31, O
maleic O
acid; O
33, O
malonic O
acid; O
39, O
propionic B-lipid
acid; I-lipid
48, O
valine. O

And O
then O
the O
12 O
annotated O
differential O
metabolites, O
which O
were O
cholesterol, O
linoleic O
acid, O
glycine, O
alanine, O
butanedioic B-lipid
acid, I-lipid
lactic O
acid, O
glucose, O
oleic O
acid, O
glucopyranose, O
sorbitol, O
proline O
and O
stearic O
acid, O
were O
explored O
by O
PLS-DA O
model O
classifying O
the O
non-ELS/MDD O
and O
healthy O
control. O

Non-esterified O
diols O
and O
alcohols O
of O
C18-PUFA O
LA O
and O
ALA O
in O
cluster O
1, O
represented O
by O
9-HODE, B-lipid
were O
enriched O
to O
a O
greater O
extent O
postprandially O
in O
pro-atherogenic O
TGRL. O

The O
raw O
LC-MS O
peak O
intensity O
ratio O
of O
PS(18:0_20:4) O
vs. O
3 O
other O
PS O
lipids O
[PS(18:0_18:1), O
PS(18:0_22:6), B-lipid
PS(18:0_20:4)] B-lipid
identified O
per O
donor O
sample. O

The O
inter-run O
accuracy O
was O
−1.6%RE O
and O
1.3%RE O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively. O

The O
LC-MS O
profiles O
demonstrated O
elevated O
levels O
of O
a O
limited O
number O
of O
polyunsaturated O
long O
chain O
PCs O
(PC(40:7), O
PC(40:6), B-lipid
PC(38:4)) B-lipid
and O
of O
SM(36:3), B-lipid
which O
has O
the O
longest O
chain O
and O
the O
highest O
unsaturation O
among O
all O
detected O
SMs. O

As O
shown O
in O
(Methanol O
precipitation) O
and O
1B O
(Methanol-ethanol O
precipitation), O
while O
most O
compounds O
were O
recovered O
and O
resolved O
using O
RPC, O
cholesterol O
and O
TG(17:2/17:2/18:0) B-lipid
were O
not O
seen O
when O
either O
precipitation O
method O
was O
used. O
also O
includes O
data O
resulting O
from O
MTBE O
extraction O
and O
MTBE:SPE O
extraction, O
as O
discussed O
in O
detail O
later. O

Lipidomic O
analysis O
also O
revealed O
changes O
in O
key O
membrane O
components, O
including O
a O
decrease O
in O
PC B-lipid
46:2. I-lipid

All O
definitions O
were O
obtained O
from O
the O
National O
Cholesterol B-lipid
Education O
Program's O
Adult O
Treatment O
Panel O
III O
report O
. O

We O
concluded O
that O
poor O
survival O
was O
due O
to O
the O
increase O
of O
PC(42:11) B-lipid
and O
with O
the O
decrease O
of O
LPE(22:0/0:0). B-lipid

Oxidative O
stress O
is O
the O
trigger O
for O
the O
production O
of O
fatty O
aldehydes, O
such O
as O
4-hydroxy-2-nonenal, B-lipid
in O
human O
metabolism. O

Measurements O
were O
performed O
in O
two O
subsets O
of O
the O
total O
study O
population O
in O
the O
Cholesterol B-lipid
and O
Pharmacogenetics O
(CAP) O
study: O
Full O
Range O
of O
Response O
(FR), O
and O
Good O
and O
Poor O
Responders O
(GPR) O
were O
100 O
individuals O
randomly O
selected O
from O
across O
the O
entire O
range O
of O
LDL-C O
responses O
in O
CAP. O

10-HdoHE, O
12-HEPE, B-lipid
and O
14-HDoHE B-lipid
are O
examples O
of O
potentially O
anti-inflammatory O
ω-3 O
fatty O
acids O
[, O
]. O

Using O
PC B-lipid
34:1 I-lipid
as O
an O
example, O
MS_2 O
CID O
of O
[M O
+ O
HCO_3 O
]_– O
(m O
/z O
820) O
suggested O
that O
it O
contained O
94% O
PC B-lipid
16:0/18:1 I-lipid
and O
6% O
PC B-lipid
18:1/16:0. I-lipid

For O
the O
extraction, O
methanol O
containing O
a O
mixture O
of O
internal O
standards O
(without O
CE B-lipid
(22:1)) I-lipid
was O
prepared, O
while O
MTBE O
containing O
cholesteryl O
ester O
(22:1) O
was O
used. O

Mediation O
analysis O
revealed O
that O
the O
lipids O
LysoPC(P-15:0), B-lipid
PC(P-34:4), B-lipid
and O
PC(38:6) B-lipid
may O
mediate O
the O
effects O
of O
ascites O
on O
recurrence. O

Furthermore, O
the O
12-LOX O
pathway O
metabolites O
like O
12-HETE, B-lipid
12-hydroxyeicosapentaenoic B-lipid
acid I-lipid
(12-HEPE), O
9-hydroxyoctadecanoic B-lipid
acid I-lipid
(9-HODE) O
and O
14-hydroxydocosahexaenoic B-lipid
acid I-lipid
(14-HDHA); O
the O
15-LOX O
metabolites O
15-HETE, B-lipid
13-HODE, B-lipid
15-HEPE B-lipid
and O
17-HDHA O
and O
various O
other O
PUFA O
metabolites O
like O
11-HETE, B-lipid
20-COOH-AA O
and O
the O
oxidative O
stress O
marker O
8iPGF_2 O
were O
all O
present O
at O
enhanced O
concentrations O
(significantly O
different) O
in O
AgP O
patient O
samples. O

The O
present O
study O
identified O
differences O
between O
subjects O
with O
RVD O
and O
those O
with O
either O
EH O
or O
normal O
blood O
pressure O
(control O
subjects) O
in O
terms O
of O
disparities O
between O
the O
2 O
groups O
in O
their O
plasma O
levels O
and O
urinary O
excretion O
of O
EETs O
and O
20-HETE B-lipid
and O
metabolism O
of O
EETs O
to O
DHETs. O

Elderly O
women O
had O
higher O
concentration O
of O
9-HODE B-lipid
and O
2,3-dinor-8-iso-PGF_2α O
than O
other O
groups O
(a O
and O
b). O

The O
fraction O
of O
heavy O
chains O
for O
PC B-lipid
34:1 I-lipid
is O
given O
by O
(0.55 O
+ O
2 O
× O
0.28) O
/ O
2 O
= O
0.55. O

Using O
PC B-lipid
18:1/16:0 I-lipid
as O
a O
model O
compound O
(10 O
μM, O
50/50, O
v/v, O
acetone/H_2 O
O O
with O
5 O
mM O
NH_4 O
HCO_3 O
), O
the O
solution O
was O
subjected O
to O
offline O
PB O
reaction O
and O
collected O
for O
nanoESI O
in O
negative O
ion O
mode O
(experimental O
details O
are O
provided O
in O
the O
ESI_† O
). O

Metabolites O
that O
contributed O
in O
both O
analyses O
were O
3,4-dihydroxybutanoic B-lipid
acid, I-lipid
docosapentaenoic B-lipid
acid, I-lipid
and O
uric O
acid. O

Low O
plasma O
levels O
of O
LysoPC(16:0) B-lipid
arose O
as O
a O
potential O
predictor O
of O
recurrence, O
especially O
in O
patients O
with O
early O
SR. O

Of O
these O
metabolites, O
2-Oxo-4-methylvaleric O
acid O
and O
4-Aminobutanoic B-lipid
acid I-lipid
showed O
the O
largest O
AUC O
values O
(AUC O
0.687 O
(95% O
CI: O
0.618–0.756), O
p O
< O
0.001; O
AUC O
0.687 O
(95% O
CI: O
0.618–0.756), O
p O
< O
0.001; O
respectively). O

For O
instance, O
in O
the O
molecular O
tandem O
mass O
spectral O
network, O
12-oxo O
LTB4 B-lipid
was O
clustered O
with O
spectra O
from O
four O
other O
unknown O
signals. O

Applying O
the O
same O
criteria O
used O
for O
the O
plasma O
lipidome O
to O
select O
the O
biomarker O
candidates, O
five O
lipids, O
LPC B-lipid
(16:1), I-lipid
PC B-lipid
(33:1), I-lipid
PC O
(35:4)B, O
PC O
(36:5)B O
and O
PC B-lipid
(36:6), I-lipid
discriminated O
meloxicam-treated O
from O
saline-treated O
cats. O

The O
EET O
pair O
displayed O
a O
slight O
difference O
in O
retention O
time O
(ΔRT=0.1) O
and O
the O
reported O
fragment O
ion O
m/z O
167 O
(red, O
) O
can O
be O
found O
in O
both O
8,9-EET B-lipid
and O
11,12-EET. B-lipid

The O
AUC O
values O
of O
MG B-lipid
(18:2), I-lipid
GNOE, O
PE B-lipid
(18:2) I-lipid
and O
ZS O
in O
the O
validation O
group O
were O
0.815, O
0.793, O
0.738 O
and O
0.930, O
respectively, O
which O
were O
all O
similar O
to O
their O
counterparts O
in O
the O
estimation O
group. O

Cholesterol B-lipid
was O
determined O
enzymatically O
using O
cholesterol O
esterase O
and O
cholesterol O
oxidase, O
intra-assay O
coefficient O
of O
variance O
(CV) O
was O
6 % O
and O
inter O
assay O
CV O
was O
3 %. O

Finally, O
we O
identified O
LysoPC(22:6) B-lipid
as O
a O
potential O
LAA O
biomarker. O

Of O
the O
differentially O
produced O
metabolites O
among O
the O
3 O
groups, O
24 O
metabolites O
(2-hydroxy-3-methylbutyric O
acid, O
3,4-dihydrxoybutyric O
acid, O
4-hydroxybutyric O
acid, O
6-aminocaproic O
acid, O
arabionse, O
arabitol, O
cellobiose, O
cytidine O
5′-diphosphocholine, O
ethanolamine, O
glyceraldehyde, O
GCDCA-3-sulfate, O
hydroxyprolyl-methionine, O
hypoxanthine, O
Ile-Thr, O
indole-3-acetamide, O
isoleucine, O
lactic O
acid, O
myo-inositol, O
pentanoic B-lipid
acid, I-lipid
threitol, O
threoninyl-methionine, O
trimethylamine O
N-oxide O
(TMAO), O
uridine, O
and O
valine) O
were O
consistently O
higher O
or O
lower. O

Elevated O
12-hydroxyeicosatetraenoic B-lipid
acid I-lipid
(12-HETE), O
15-HETE, B-lipid
sphingosine, O
γ-glutamyl O
oxidative O
stress-associated O
metabolites, O
xanthine, O
amino O
acids O
serine, O
glycine O
and O
aspartate, O
and O
a-cylcarnitines O
were O
strongly O
associated O
with O
the O
presence O
of O
HCC. O

Particularly, O
SM(18:1/24:0) B-lipid
was O
found O
to O
inversely O
correlate O
with O
MELD O
score, O
and O
positively O
correlate O
with O
inflammation O
grades O
in O
CHB O
patients; O
phytosphingosine O
and O
dihydrosphingosine O
were O
found O
to O
be O
decreased O
in O
the O
sera O
of O
HCC O
patients O
compared O
to O
cirrhosis O
patients. O

For O
example, O
recovery O
of O
PC(19:0/15:1) B-lipid
(p<0.001) O
increased O
by O
40%, O
and O
PE(20:3/18:1) B-lipid
(p=0.012) O
increased O
by O
58%. O

Ion O
mobilograms O
of O
the O
precursor O
and O
product O
ions O
obtained O
from O
negative O
ion O
CTS O
of O
(A) O
PC(17:0/20:4), B-lipid
(B) O
PE(17:0/20:4), B-lipid
(C) O
PA(17:0/20:4), B-lipid
(D) O
PS(17:0/20:4), B-lipid
(E) O
PI(17:0/20:4), B-lipid
and O
(F) O
SM(d18:1/18:0). B-lipid

The O
metabolites O
that O
had O
the O
largest O
difference O
were O
succinic O
acid, O
malate, O
and O
butanoic B-lipid
acid. I-lipid

Additionally, O
we O
observe O
an O
increased O
incorporation O
of O
long, O
odd O
chained O
FAs, O
such O
as O
FA B-lipid
17:0, I-lipid
17:1, O
15:0, O
and O
19:1, O
into O
lipid O
side O
chains, O
most O
likely O
because O
of O
the O
dairy-based O
premature O
infant O
diet. O

A. O
12-HETE, B-lipid
B. O
Taurine, O
C. O
Ceramide(d18:1/20:0), B-lipid
D. O
Sphingomyelin O
SM(d18:1/26:1 O
OH), O
E. O
Xanthosine, O
F. O
Plasmalogen O

It O
is O
worth O
noting O
that O
by O
using O
a O
much O
larger O
sampling O
size, O
i.e., O
70 O
plasma O
samples, O
previously O
Wang O
et O
al. O
discovered O
significant O
changes O
at O
subclass O
level O
for O
PE B-lipid
38:4 I-lipid
and O
PE B-lipid
38:6 I-lipid
in O
T2D O
plasma O
samples. O

Cholesterol B-lipid
levels O
changed O
very O
little. O

Palmitic B-lipid
acid I-lipid
(C16:0) O
is O
reported O
to O
induce O
lipoapoptosis O
in O
hepatocytes O
via O
mechanisms, O
including O
mitochondrial O
dysfunction O
and O
stress O
of O
endoplasmic O
reticulum. O

We O
highlight O
that O
none O
of O
the O
markers O
identified O
in O
this O
study O
have O
previously O
been O
related O
to O
CRC O
with O
the O
exception O
of O
LPC B-lipid
(18:1). I-lipid

Negative O
ion O
CTS O
analysis O
of O
phospholipid O
standards O
(PC, O
PE, O
PA, O
PS, O
and O
PI) O
containing O
heptadecanoic B-lipid
acid I-lipid
(17:0) O
esterified O
to O
the O
sn O
-1 O
position O
of O
the O
glycerol O
backbone O
and O
arachidonic O
acid O
(20:4) O
at O
the O
sn O
-2 O
position O
of O
the O
glycerol O
backbone O
and O
the O
sphingomyelin O
standard, O
SM(d18:1/18:0), B-lipid
was O
completed. O

The O
compositional O
changes O
of O
the O
C18:1 O
Δ9 O
and O
Δ11 O
isomers O
of O
PC B-lipid
15:0_18:1 I-lipid
were O
not O
statistically O
different O
between O
the O
normal O
and O
cancerous O
tissue O
samples. O

Interestingly, O
we O
demonstrated O
that O
most O
of O
the O
analysed O
tear O
metabolites, O
like O
PC B-lipid
34:1, I-lipid
PC B-lipid
36:2 I-lipid
and O
PC B-lipid
40:4, I-lipid
C0, O
C2, O
C3, O
Leu/Ile/Pro, O
Phe, O
Tyr, O
Glu, O
Met, O
and O
Lys/Gln O
were O
more O
retained O
in O
the O
first O
section O
of O
the O
imbibed O
paper O
strip. O

Interestingly, O
a O
significant O
decrease O
in O
LPC B-lipid
(18:1) I-lipid
was O
observed O
in O
non-advanced O
CRC O
patients O
but O
an O
increase O
in O
our O
patients O
with O
metastatic O
CRC, O
suggesting O
that O
this O
metabolite O
may O
potentially O
be O
useful O
as O
a O
biomarker O
of O
the O
progression O
of O
this O
disease. O

The O
zoomed-in O
region O
in O
shows O
two O
pairs O
of O
CC O
diagnostic O
ions O
(m O
/z O
171, O
197; O
m O
/z O
199, O
225) O
of O
C18:1, O
suggesting O
that O
PC B-lipid
18:1/16:0 I-lipid
contains O
two O
CC O
isomers, O
PC O
18:1(Δ9)/16:0 O
and O
PC O
18:1(Δ11)/16:0. O

We O
manually O
selected O
a O
combination O
of O
three O
metabolites O
namely O
pentadecanoic B-lipid
acid, I-lipid
1-linoleoylglycerophosphocholine O
and O
linoleoyl O
carnitine O
to O
create O
a O
biomarker O
model O
to O
distinguish O
between O
these O
two O
groups O
using O
RF O
(random O
forest) O
algorithm. O

Compared O
to O
elderly O
levels O
of O
eicosapentaenoic B-lipid
acid I-lipid
(EPA) O
decreased O
also O
in O
centenarians. O

, O
Our O
data O
clearly O
suggest O
that O
PC B-lipid
16:0_18:1 I-lipid
may O
contain O
four O
structural O
isomers O
from O
combinations O
of O
two O
sn O
-isomers O
and O
two O
CC O
location O
isomers O
of O
the O
C18:1. O

Moreover, O
serum O
levels O
of O
lysoPC(18:2), B-lipid
PhePhe, O
uridine, O
taurine, O
L-threonine, O
and O
(R)-3-Hydroxy-hexadecanoic B-lipid
acid I-lipid
were O
significantly O
correlated O
with O
disease O
activity O
scores O
(all O
p<0.05) O
in O
AOSD O
patients. O

(A) O
Receiver O
operating O
characteristic O
(ROC) O
plot O
obtained O
by O
combining O
three O
metabolites O
namely O
pentadecanoic B-lipid
acid, I-lipid
linoleoyl O
carnitine O
and O
1-linoleoylglycerophosphocholine. O

The O
RT O
and O
fragmentation O
pattern O
were O
virtually O
identical O
between O
marker O
and O
standard O
in O
the O
cases O
of O
sphinganine O
(Fig. ) O
and O
PC B-lipid
(18:1) I-lipid
(Fig. O

Due O
to O
all O
these O
neuroprotective O
properties, O
decreased O
plasma O
levels O
of O
LysoPC(16:0) B-lipid
could O
contribute O
to O
an O
early O
SR O
risk. O

Panel O
A, O
Concentrations O
(μmol/l) O
of O
lignoceric O
acid O
(FA(24:0)) O
and O
nervonic O
acid O
(FA(24:1)) O
in O
hepatocellular O
carcinoma O
(HCC; O
20 O
cases), O
acute O
myelogenous O
leukemia O
(AML; O
22 O
cases), O
liver O
cirrhosis O
(LC; O
7 O
cases) O
and O
healthy O
volunteers O
(HV; O
6 O
subjects). O

Moreover, O
lysoPC O
(22:6) O
and O
LPA B-lipid
(18:1) I-lipid
were O
revealed O
as O
independent O
factors O
for O
future O
LC O
incident O
via O
logistic O
regression O
analysis. O

Specifically, O
a O
combination O
profile O
of O
LysoPC O
18.2, O
L-Proline, O
Hexadecanoic B-lipid
acid, I-lipid
Octadecanoic B-lipid
acid, I-lipid
Phenylalanine O
and O
LysoPC O
16:1 O
showed O
close O
correlation O
for O
eight O
weight-losing O
samples O
(≥5% O
weight O
loss) O
and O
nine O
weight-stable O
samples O
(<5%weight O
loss) O
between O
predicted O
and O
actual O
weight O
change O
(r O
= O
0.976, O
p O
= O
0.0014). O

The O
only O
statistically O
significant O
PC O
lipid O
that O
increased O
in O
fatalities O
was O
PC(16:0/16:0) B-lipid
(P O
value O
0.003) O
( O
and O
). O

Furthermore, O
overexpression O
of O
an O
ω O
-hydroxylase O
isozyme, O
which O
increased O
the O
production O
of O
20-HETE B-lipid
in O
blood O
vessels, O
caused O
endothelial O
dysfunction. O

Another O
study, O
comprising O
of O
30,252 O
breast O
cancer O
patients, O
revealed O
that O
eicosapentaenoic B-lipid
acid I-lipid
and O
docosahexaenoic B-lipid
acid I-lipid
were O
significantly O
inversely O
associated O
with O
risk O
for O
breast O
cancer O
(HR: O
0.70, O
95% O
CI: O
0.54–0.90; O
HR: O
0.67, O
95% O
CI: O
0.52–0.87). O

Only O
a O
few O
correlations O
were O
found O
for O
PC B-lipid
28:1, I-lipid
PC B-lipid
30:2, I-lipid
PC B-lipid
40:1, I-lipid
PC B-lipid
42:6, I-lipid
GPCe O
38:6 O
and O
SM B-lipid
22:3 I-lipid
within O
the O
respective O
lipid O
classes. O

From O
65 O
differential O
lipids O
highlighted O
between O
responder O
(RP) O
vs O
not O
responder O
(NRP) O
patients, O
five O
lipids O
were O
validated O
to O
predict O
response O
at O
T0: O
SM(d18:2/18:1), B-lipid
LysoPC O
(16:0/0:0), O
LysoPC O
(15:1(9z)/0:0), O
Lyso O
PE B-lipid
(22:5/0:0) I-lipid
and O
m/z= O
842.90 O
corresponding O
to O
a O
PC O
containing O
2 O
fatty O
acids O
of O
40 O
carbons O
totally. O

(A) O
Unsaturated O
fatty O
acids O
(contain O
one O
or O
more O
C=C O
double O
bonds) O
are O
prone O
to O
lipid O
peroxidation, O
resulting O
in O
the O
formation O
of O
lipid O
aldehydes, O
acrolein O
(AL), O
malondialdehyde O
(MDA) O
and O
4-hydroxynonenal B-lipid
(HNE). O

Since O
docosahexaenoic B-lipid
acid I-lipid
was O
the O
only O
lipid O
that O
was O
found O
in O
this O
study O
the O
cause O
of O
its O
enrichment O
in O
incubations O
with O
alpha-PEP O
remains O
speculative. O

For O
example, O
PC38:6 B-lipid
has O
been O
associated O
with O
an O
increased O
risk O
of O
diabetes. O

Linoleic B-lipid
acid, I-lipid
a O
doubly O
unsaturated O
fatty O
acid O
and O
an O
omega-6 O
fatty O
acid, O
could O
improve O
the O
age-associated O
decline O
in O
cognition O
and O
neural O
function O
in O
rats O
due O
to O
the O
enhancement O
of O
protective O
signaling, O
the O
alterations O
in O
membrane O
microstructures, O
the O
decreases O
in O
inflammation, O
and O
the O
prevention O
of O
the O
accumulation O
of O
polyubiquitinated O
protein O
aggregates O
in O
critical O
regions O
of O
the O
brain. O

The O
earlier O
eluting O
isomer O
of O
PC(38:4) B-lipid
gave O
rise O
to O
the O
fragment O
ions O
504.3, O
528.3 O
and O
534.3, O
matching O
with O
the O
potential O
fragmentation O
pattern O
of O
PC(18:1/20:3). B-lipid

Adjusted O
OR O
(95% O
CI) O
of O
MI, O
IS, O
and O
ICH O
for O
Mean O
Particle O
Diameter, O
Cholesterol, B-lipid
Triglycerides, O
and O
Apolipoproteins O
as O
Measured O
by O
Nuclear O
Magnetic O
Resonance O
Spectroscopy O
Estimates O
are O
ORs O
per O
1-SD O
higher O
metabolic O
marker. O

By O
way O
of O
contrast, O
20-HETE, B-lipid
which O
inhibits O
Na_+ O
-K_+ O
-2Cl_− O
cotransporter O
activity O
in O
the O
TAL, O
will O
promote O
Na_+ O
reabsorption O
and O
elevate O
blood O
pressure O
when O
deficient, O
as O
in O
the O
Dahl O
salt-sensitive O
rat. O

They O
observed O
that O
a O
few O
lipids O
like O
LysoPC O
(16:0), O
LPA B-lipid
(16:0/0:0) I-lipid
and O
LPA B-lipid
(0:0/16:0) I-lipid
were O
aberrantly O
expressed O
in O
CTCL O
plasma O
in O
positive O
and O
negative O
modes. O

Conversion O
to O
AD O
(b.) O
preferentially O
channels O
putrescine O
towards O
the O
production O
of O
spermidines O
and O
spermines, O
whereas O
in O
stable O
MCI O
(a.) O
the O
fate O
of O
putrescine O
is O
the O
formation O
of O
N-acetylputrescine O
and O
4-aminobutanal. B-lipid

For O
the O
HETEs, O
compounds O
biosynthesized O
via O
the O
LOX O
pathway, O
a O
dramatic O
increase O
was O
visible, O
in O
particular O
for O
12-HETE B-lipid
and O
5-HETE B-lipid
(Fig. ). O

Arachidonic O
acid O
(C20:4) O
released O
by O
phospholipases O
from O
cell O
membrane O
is O
metabolized O
by O
lipoxygenases O
(LOX); O
especially, O
5-LOX O
generates O
5-HETE B-lipid
and O
leukotriene O
B_4 O
from O
arachidonic O
acid O
(C20:4). O

The O
transitions O
monitored O
were: O
337.2>207.1 O
and O
337.2>319.3 O
for O
14(15)-DiHET O
(rt: O
5.4 O
min), O
337.2>167.0 O
and O
337.2>319.3 O
for O
11(12)-DiHET O
(rt: O
5.7 O
min), O
319.2>275.3, O
319.2>301.3 O
and O
319.2>289.2 O
for O
20-HETE B-lipid
(rt: O
6.6 O
min), O
319.2>219.2, O
319.2>301.3 O
and O
319.2>175.0 O
for O
15-HETE B-lipid
(rt: O
7.6 O
min), O
319.2>179.2, O
319.2>301.3 O
and O
319.2>257.2 O
for O
12-HETE B-lipid
(rt: O
8.2 O
min), O
303.2>259.2, O
303.2>205.1 O
and O
303.2>58.7 O
for O
AA O
(rt: O
15.1 O
min) O
and O
311.3>267.3 O
for O
AA-d8 O
(rt: O
14.9 O
min). O

Of O
all O
the O
metabolites, O
we O
found O
that O
20-HETE B-lipid
had O
the O
highest O
fold-change. O

Glutamate, O
linoleic O
acid, O
and O
PC B-lipid
(16:0/0:0) I-lipid
were O
selected O
due O
to O
their O
high O
abundance O
and O
important O
roles O
in O
biochemistry. O

Among O
these O
4 O
metabolites, O
oral O
fat-specific O
correlation O
was O
seen O
only O
with O
LysoPC(16:0) B-lipid
and O
SM(d18:1/24:1) B-lipid
(i,k–n). O

Due O
to O
its O
chemotactic O
properties, O
12-HETE B-lipid
has O
been O
linked O
to O
healing O
processes O
during O
inflammation O
[, O
]. O

High O
concentrations O
of O
PGs, O
LTB4 B-lipid
and O
cysteinyl-leukotrienes O
have O
been O
reported O
to O
promote O
the O
accumulation O
of O
inflammatory O
cells O
such O
as O
polymorphonuclear O
leukocytes O
(PMNs) O
by O
increasing O
the O
blood O
flow O
and O
vascular O
permeability O
. O

For O
the O
metabolites, O
lysoPC(16:0), B-lipid
PC(P-16:0/20:4), B-lipid
linoleic O
acid, O
and O
linoleyl O
carnitine, O
the O
analytical O
variation O
values O
were O
less O
than O
half O
of O
the O
individual O
variation O
values O
(CVa O
< O
1/2 O
CVi) O
indicating O
adequate O
precision. O

Particularly, O
decreased O
LysoPG(20:5) B-lipid
level O
was O
identified O
as O
the O
most O
important O
prognostic O
feature O
in O
our O
model, O
which O
may O
provide O
additional O
prognostic O
information O
for O
EOC. O

Interestingly, O
the O
spectrum O
at O
m/z O
of O
855.6 O
corresponded O
to O
[M + Na]_+ O
ion O
of O
PI34:3. B-lipid

LTB4 B-lipid
was O
found O
to O
be O
significant O
owing O
to O
its O
apparent O
complete O
depletion O
in O
serum O
of O
CLL O
patients. O

To O
confirm O
their O
identity, O
two O
marker O
fatty O
acids, O
arachidonic O
acid O
and O
eicosatrienoic B-lipid
acid, I-lipid
were O
matched O
against O
the O
retention O
times O
of O
their O
corresponding O
standards O
on O
a O
C4 O
reversed O
phase O
column. O

However, O
there O
are O
several O
standards O
with O
S/N O
less O
than O
1500; O
heptanoic B-lipid
acid I-lipid
(S/N O
= O
18), O
decanoic B-lipid
acid I-lipid
(S/N O
= O
83), O
oxalic O
acid O
(S/N O
= O
47) O
and O
adipic O
acid O
(S/N O
= O
87). O

For O
example, O
positive O
correlations O
between O
LPI B-lipid
(16:0) I-lipid
with O
palmitic O
acid O
(16:0) O
and O
hexadecanoylcarnitine O
(C16) O
were O
observed. O

The O
overweight O
group O
showed O
significant O
decreases O
in O
11 O
metabolites—lysoPCs O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:2, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
and O
PC O
(18:0/20:4)—and O
significant O
increases O
in O
6 O
metabolites—L-leucine, O
palmitic O
amide, O
L-octanoylcarnitine, O
decanoylcarnitine, O
PC B-lipid
(18:2/18:2), I-lipid
and O
lactosylceramide. O

However, O
arachidonic O
acid O
(ARA, O
20:4) O
and O
docosahexaenoic B-lipid
acid I-lipid
(DHA O
22:6), O
which O
are O
long-chain O
polyunsaturated O
acids O
(PUFAs), O
were O
decreased O
in O
R_AT O
and O
R_BT O
, O
respectively O
(Shown O
in O
Figures O
, O
). O

In O
this O
study O
as O
well, O
a O
comparison O
between O
the O
OSCC O
and O
OD O
before O
surgery O
revealed O
a O
significant O
increase O
in O
nonanoic B-lipid
acid I-lipid
in O
the O
OSCC O
group, O
consistent O
with O
Scachez O
et O
al., O
who O
investigated O
lung O
cancer. O

report O
concentrations O
after O
consumption O
of O
JWH-018 O
and O
JWH-073, O
which O
were O
in O
the O
low O
nanogram O
per O
milliliter O
range O
for O
the O
main O
metabolites O
(JWH-018 O
5-hydroxypentyl O
23 O
ng/mL/26 O
ng/mL; O
JWH-018 O
pentanoic B-lipid
acid I-lipid
16.5 O
ng/mL/16 O
ng/mL, O
JWH-073 O
butanoic B-lipid
acid I-lipid
6.2 O
ng/mL). O

The O
diagnostic O
utility O
in O
combining O
measurement O
of O
the O
up-regulated O
(decanoylcarnitine, O
lysoPC(16:0), B-lipid
lysoPC(18:0), B-lipid
lysoPC(16:1) B-lipid
and O
octanoylcarnitine) O
with O
the O
down-regulated O
(linoleic O
acid O
and O
uric O
acid) O
was O
relatively O
high, O
with O
a O
sensitivity O
and O
specificity O
up O
to O
90.2% O
and O
96.0%, O
respectively. O

In O
addition, O
three O
downregulated O
LPCs, O
LPC(14:0), B-lipid
LPC(20:3), B-lipid
and O
LPC(22:6), B-lipid
were O
found O
for O
this O
comparison O
of O
patient O
classes O
by O
random O
forests. O

The O
methanol O
used O
for O
extraction O
was O
spiked O
with O
the O
following O
compounds, O
chosen O
to O
encompass O
most O
of O
the O
retention O
time-m/z O
space O
covered O
by O
the O
method, O
while O
being O
undetected O
in O
nonspiked O
human O
serum O
extracts: O
tryptophan-d_5 O
(indole-d_5 O
), O
PC(13:0/0:0), B-lipid
NEFA(19:0), O
and O
dehydrocholic O
acid. O

Similarly, O
cholesterol, O
Cer(d18:0/24:1) B-lipid
(p<0.001), O
TG(17:2/17:2/18:2) B-lipid
(p=0.00261), O
and O
TG(17:2/17:2/18:0) B-lipid
(p=0.00291) O
were O
detected O
when O
MTBE O
was O
used O
but O
were O
not O
observed O
when O
methanol O
alone O
was O
used. O

PA B-lipid
(38:4) I-lipid
was O
the O
only O
species O
identified O
in O
virions, O
and O
it O
was O
also O
elevated O
in O
infected O
relative O
to O
mock-infected O
cells. O

For O
instance, O
the O
peak O
at O
m/z O
718.6 O
in O
141 Da O
NLS O
(monoisotopic O
molecular O
mass: O
717.6 Da, O
RT: O
5.2 min) O
was O
identified O
as O
PE B-lipid
16:0_18:1, I-lipid
based O
on O
the O
detection O
of O
fatty O
acyl O
anions O
at O
m/z O
255 O
(C16:0) O
and O
m/z O
281 O
(C18:1) O
(Supplementary O
Fig. O

The O
results O
are O
listed O
in O
, O
where O
AFMK O
and O
sphinganine O
demonstrated O
relatively O
high O
sensitivity O
(≥80%), O
and O
inosine, O
indoleacetic O
acid O
and O
PS(O-18:0/0:0) B-lipid
yielded O
specificity O
of O
more O
than O
80%. O

Compared O
with O
HCs, O
DN-MDD O
exhibited O
a O
decrease O
in O
fatty O
acids, O
including; O
capric O
acid, O
cis-9-palmitoleic O
acid, O
dodecanoic B-lipid
acid, I-lipid
oleic O
acid O
and O
palmitic O
acid, O
and O
the O
polyunsaturated O
fatty O
acids O
(PUFAs), O
including; O
eicosapentaenoic B-lipid
acid I-lipid
(EPA,ω-3) O
and O
arachidonic O
acid O
(AA,ω-6) O
which O
is O
generated O
from O
phospholipids O
through O
phospholipase O
A2 O
with O
lysophospholipids O
as O
a O
by-product. O

A O
total O
of O
2 O
volatile O
metabolites O
(2-methylbutanal O
and O
decanoic O
acid) O
were O
able O
to O
distinguish O
the O
patients O
with O
CD20_− O
B-NHL O
and O
CD20_+ O
B-NHL O
with O
significantly O
higher O
concentration O
levels O
in O
patients O
with O
CD20_− O
B-NHL. O

These O
are O
palmitic O
acid, O
stearic O
acid, O
oleic O
acid, O
benzoic O
acid, O
butanoic B-lipid
acid, I-lipid
cholesterol, O
glycine, O
3-heptanone, O
4-heptanone, O
hexanal, B-lipid
1-tetradecanol O
and O
naphthalene O
. O

Among O
the O
20 O
candidate O
lipid O
markers, O
decreasing O
levels O
were O
observed O
in O
18 O
lipid O
species O
in O
SqCC O
patients; O
however, O
2 O
lipid O
species, O
PC(38:6) B-lipid
and O
PI(38:4), B-lipid
presented O
an O
increased O
level O
in O
SqCC O
plasma O
when O
compared O
with O
the O
controls. O

Equally O
good O
matching O
was O
observed O
for O
retention O
times O
of O
authentic O
standard O
of O
SM B-lipid
(36:2) I-lipid
and O
the O
observed O
SM B-lipid
(36:2) I-lipid
(not O
shown). O

Abbreviations: O
MSA: O
multiple O
system O
atrophy; O
PSP: O
progressive O
supranuclear O
palsy; O
AUC: O
area O
under O
the O
curve; O
FA: O
fatty O
acid; O
LysoPC(16:0): B-lipid
lysophosphatidylcholine O
(16:0); O
DHEAS: O
dehydroisoandrosterone O
3-sulfate; O
SDMA: O
symmetric O
dimethylarginine O
fatty O
acid; O
AC: O
acylcarnitine; O
Met: O
methionine. O

MS/MS O
fragmentation O
of O
PC(40:7) B-lipid
lead O
to O
its O
identification O
as O
PC(18:1/22:6) B-lipid
based O
on O
the O
fragment O
ions O
550.3 O
([M+Li-R1′CHCO]+) O
and O
556.3 O
([M+Li-R1CO2Li]+). O

This O
finding O
is O
aligned O
with O
earlier O
studies O
that O
illuminated O
salutary O
effects O
of O
longer O
unsaturated O
FFAs, O
such O
as O
oleate O
and O
eicosapentaenoic B-lipid
acid, I-lipid
on O
inflammation, O
endoplasmic O
reticulum O
stress, O
and O
eventually O
better O
podocyte O
and O
pancreatic O
cell O
survival O
compared O
with O
the O
effect O
of O
saturated O
FFA O
palmitate O
(–). O

Particularly, O
two O
of O
the O
three O
candidate O
metabolites O
that O
we O
identified O
as O
having O
the O
best O
predicting O
power, O
PE B-lipid
(18:2) I-lipid
and O
glycerophospho-N-ethanolamine, O
belonged O
to O
this O
category. O

The O
meta-analysis O
provided O
some O
evidence O
for O
the O
involvement O
of O
ω O
-3 O
fatty O
acids O
(including O
docosahexaenoic B-lipid
acid I-lipid
and O
high-density O
lipoproteins). O

By O
UPLC-MS, O
we O
identified O
2 O
metabolites O
(with O
an O
LoA O
≤ O
3) O
that O
were O
higher O
in O
PRP O
compared O
with O
PFP O
samples: O
PE(18:0/18:2) B-lipid
and O
PC(P-16:0/20:4). B-lipid

Excellent O
recoveries O
of O
Cer(22:0) B-lipid
and O
Cer(24:0) B-lipid
from O
plasma O
and O
from O
BSA O
were O
obtained O
(see O
). O

Chromatograms O
from O
quality O
control O
samples O
(QCs) O
at O
pH O
7 O
and O
pH O
2 O
(1: O
3-methylbut-3-en-2-ol; O
2: O
1,4-xylene; O
3: O
2,7-dimethyloctan-1-ol; O
4: O
2-(4-methylcyclohex-3-en-1-yl)propan2-ol O
; O
5: O
3,7-dimethyloct-7-en-1-ol; O
6: O
1,3-benzothiazol; O
7: O
decan-1-ol; O
8: O
pentadecan-2-one; O
9: O
cyclohexanone; O
10: O
4-methyheptan-2-one; O
11: O
2-methylpentan-1,3-diol; O
12: O
4-methylbenzaldehyde; O
13: O
methyl O
benzoate; O
14: O
nonanoic B-lipid
acid; I-lipid
15: O
decanoic O
acid). O

Serum O
alanine O
aminotransferase O
(ALT), O
aspartate O
aminotransferase O
(AST), O
gamma-glutamyl O
transferase O
(GT), O
glucose, O
cholesterol, O
and O
triglyceride O
concentrations O
were O
measured O
with O
ALT, O
AST, O
GT, O
Glucose, O
Cholesterol, B-lipid
and O
Triglycerides O
System O
Reagent, O
(Beckman O
Coulter O
Biomedical). O

For O
example, O
signal O
intensity O
drops O
between O
the O
first O
and O
the O
sixth O
exhalation O
for O
4-hydroxy-2-nonenal B-lipid
is O
around O
50%, O
for O
2-dodecenal O
the O
drop O
is O
around O
30%, O
whereas O
for O
4-hydroxy-2,6-pentadecadienal B-lipid
signal O
intensity O
remains O
stable O
(or O
even O
increases O
after O
the O
first O
exhalation). O

oxoODE O
(21.9% O
in O
PMC), O
13-HOTrE O
(25.5% O
in O
plasma), O
and O
20-HETE B-lipid
(21.8% O
in O
PMC) O
at O
the O
lowest O
QC1level. O

It O
is O
observed O
that O
pyridoxine O
levels O
are O
lowered O
in O
the O
stages O
of O
II, O
III, O
and O
IV O
as O
compared O
to O
stage O
0 O
and O
I. O
Cholesterol, B-lipid
taurocholic O
acid, O
and O
deoxycholic O
acid O
are O
three O
related O
metabolites O
participating O
in O
bile O
acid O
biosynthesis O
whose O
levels O
had O
increased O
in O
the O
II O
and O
III O
stage O
groups. O

Adult O
PKU, O
Treatment, O
Cholesterol, B-lipid
Lipoprotein O
subclasses, O
NMR O

A O
receiver O
operator O
curve O
analysis O
revealed O
that O
the O
combination O
of O
4-hydroxypentenoic B-lipid
acid, I-lipid
arabinose, O
glycochenodeoxycholate-3-sulfate, O
isoleucine, O
serine, O
and O
xanthine O
produced O
a O
moderate O
diagnostic O
score O
with O
a O
sensitivity O
(specificity) O
of O
75% O
(78%) O
for O
distinguishing O
OSA O
from O
those O
without O
OSA. O

The O
ions O
at O
m/z O
687, O
715, O
743, O
771, O
and O
797 O
were O
identified O
as O
SM(d18:1/16:0), B-lipid
SM(d18:1/18:0), B-lipid
SM(d18:1/20:0), B-lipid
SM(d18:1/22:0), B-lipid
and O
SM(d18:1/24:1), B-lipid
respectively. O

In O
brief, O
urine O
sample O
preparation O
consisted O
of O
1) O
pre-extraction O
on O
a O
Sep-Pak O
C18 O
column O
with O
the O
recovery O
standard O
medroxyprogesterone, O
2) O
enzymatic O
hydrolysis O
with O
sulfatase O
and O
β-glucuronidase/arylsulfatase, O
3) O
extraction O
of O
the O
free O
steroids O
from O
the O
hydrolysis O
mixture O
again O
on O
a O
Sep-Pak O
C18 O
cartridge, O
4) O
derivatization O
with O
methoxyamine O
HCl O
2% O
in O
pyridine O
at O
60°C O
for O
one O
hour O
after O
adding O
the O
two O
standards O
Stigmasterol B-lipid
and O
3β5β-TH-aldosterone O
and O
derivatization O
with O
Trimethylsilylimidazole O
(TMSI) O
at O
100°C O
for O
16 O
hours, O
5) O
purification O
by O
gel O
filtration O
on O
a O
Lipidex O
5000 O
column. O

Besides O
the O
well-described O
AA O
metabolites, O
oxylipins O
derived O
from O
linoleic O
acid, O
dihomo-γ-linolenic O
acid, O
α-linolenic O
acid, O
eicosapentaenoic B-lipid
acid I-lipid
and O
docosahexaenoic B-lipid
acid I-lipid
were O
included. O

The O
results O
demonstrated O
that O
the O
phosphatidic O
acid O
and O
CE B-lipid
(18:0) I-lipid
levels O
in O
HU O
were O
lower O
than O
those O
in O
HU+NAFLD; O
by O
contrast, O
the O
inosine O
levels O
in O
HU O
were O
higher O
than O
those O
in O
HU+NAFLD. O

Based O
on O
this O
pattern, O
a O
higher O
LPC B-lipid
16:1 I-lipid
level O
was O
detected O
in O
the O
obese O
group, O
while O
higher O
levels O
of O
other O
LPC O
species O
were O
observed O
in O
nonobese O
subjects. O

Samples O
were O
extracted O
by O
adding O
100 O
µL O
of O
serum O
to O
1 O
mL O
of O
ice-cold O
extraction O
solvent O
consisting O
of O
methanol/chloroform O
(v:v O
= O
3:1) O
containing O
10 O
µg/mL O
heptadecanoic B-lipid
acid I-lipid
and O
10 O
µg/mL O
norleucine O
as O
internal O
standards. O

Interestingly, O
PC B-lipid
(34:2), I-lipid
PC B-lipid
(34:1), I-lipid
PC B-lipid
(36:3), I-lipid
and O
PC B-lipid
(36:2) I-lipid
increased O
in O
both O
tissues O
and O
sera O
of O
MF O
patients, O
whereas O
SM B-lipid
(16:0), I-lipid
PC B-lipid
(32:0), I-lipid
and O
PC B-lipid
(38:4) I-lipid
levels O
increased O
in O
the O
sera O
but O
decreased O
in O
the O
tissues O
of O
MF O
patients O
compared O
to O
control O
subjects. O

Norepinephrine O
(d_6 O
), O
cholic O
acid O
(d_4 O
), O
epinephrine O
(d_3 O
), O
dopamine O
(d_4 O
), O
melatonin O
(d_4 O
), O
4-aminobutanoic B-lipid
acid I-lipid
(d_6 O
) O
and O
phenylalanine O
(d_5 O
) O
were O
obtained O
from O
CDN O
Isotopes O
(Point-Claire, O
QC, O
Canada), O
while O
_13 O
C_6 O
- O
thyroxine O
was O
purchased O
from O
Toronto O
Research O
Chemicals O
(Toronto, O
ON, O
Canada). O

In O
particular, O
FA B-lipid
(20:4), I-lipid
or O
arachidonic O
acid, O
is O
a O
precursor O
of O
prostaglandins O
that O
were O
shown O
to O
be O
elevated O
in O
BCC O
compared O
with O
normal O
skin, O
and O
are O
predictive O
of O
tumor O
aggressiveness O
(, O
). O

The O
exclusive O
increase O
of O
PC(16:0/16:0) B-lipid
supports O
fatty O
liver O
disease O
with O
EVD, O
as O
PC(32:0) B-lipid
was O
recently O
reported O
as O
a O
potential O
signature O
of O
progressive O
forms O
of O
fatty O
liver O
disease. O

The O
differentiated O
metabolites O
identified O
in O
the O
CD O
samples O
included O
tyrosine, O
an O
ornithine O
isomer, O
arachidonic O
acid, O
eicosatrienoic B-lipid
acid, I-lipid
docosatetraenoic B-lipid
acid, I-lipid
a O
sphingomyelin, O
a O
ceramide, O
and O
dimethylsphinganine. O

The O
linoleate O
metabolites O
13-HODE B-lipid
+ O
9-HODE B-lipid
were O
also O
significantly O
higher O
in O
C-3N O
subjects. O

Stability O
of O
the O
Cer(22:0) B-lipid
and O
Cer(24:0) B-lipid
in O
the O
human O
plasma O
was O
evaluated O
under O
a O
variety O
of O
conditions O
to O
establish O
length O
of O
storage O
and O
sample O
processing O
conditions O
(see O
). O

Although O
ions O
at O
m O
/z O
445 O
and O
m O
/z O
419 O
were O
each O
detected O
at O
low O
abundances O
in O
CID O
of O
PC B-lipid
16:0/18:1 I-lipid
and O
PC B-lipid
18:1/16:0, I-lipid
they O
were O
later O
proved O
to O
be O
the O
“sn O
-1 O
fragments” O
resulting O
from O
corresponding O
sn O
-isomers, O
which O
are O
present O
as O
minor O
impurities O
in O
the O
supplied O
samples. O

Hexadecanoic B-lipid
acid. I-lipid

 , O
compared O
with O
the O
corresponding O
levels O
in O
HC, O
the O
levels O
of O
saturated O
and O
monounsaturated O
PCs O
such O
as O
PC(15:0/18:1), B-lipid
PC(18:0/16:0) B-lipid
and O
PC(18:0/20:1) B-lipid
were O
significantly O
increased, O
whereas O
the O
levels O
of O
polyunsaturated O
PCs O
such O
as O
PC(17:2/2:0), B-lipid
PC(18:4/3:0), B-lipid
PC(15:0/18:2), B-lipid
PC(16:0/18:3), B-lipid
PC(17:0/18:2), B-lipid
PC(18:2/18:2), B-lipid
PC(16:0/20:3), B-lipid
PC(15:0/22:6) B-lipid
and O
PC(24:4/17:2) B-lipid
significantly O
decreased O
in O
early-stage O
NSCLC O
patients. O

shows O
down-regulation O
of O
fatty O
acid O
of O
tetracosahexaenoic O
acid O
and O
3-hydroxy-eicosanoic B-lipid
acid I-lipid
in O
HCC O
cases O
compared O
to O
cirrhotic O
controls. O

4-hydroxy-2-dodecenal B-lipid
shows O
a O
deviating O
pattern O
that O
may O
be O
caused O
by O
an O
interfering O
peak. O

Stability O
of O
5,6-EET B-lipid
and O
deuterated O
5,6-EET-d_11 O
decreased O
to O
61 O
and O
57%, O
respectively, O
at O
this O
storage O
condition O
for O
plasma O
extract O
at O
24 O
h O
relative O
to O
0 O
h. O

In O
this O
model, O
myo-inositol O
and O
hexadecenoic B-lipid
acid I-lipid
were O
associated O
with O
long O
survival O
time. O

LPA(16:0) B-lipid
was O
profiled O
by O
modification O
of O
a O
previously O
described O
method. O

Lactobacilli O
produce O
lactic O
acid O
and O
acetic O
acid O
from O
glucose O
and O
fructose O
by O
a O
fermentation O
process O
, O
while O
Veillonella O
transform O
lactic O
acid O
into O
acetic O
acid O
and O
propionic B-lipid
acid I-lipid
. O

Regarding O
correlation O
analysis, O
20-HETE B-lipid
circulating O
levels O
correlated O
positively O
with O
BMI O
and O
diastolic O
blood O
pressure O
(r O
= O
0.427, O
p O
= O
0.007; O
r O
= O
0.365, O
p O
= O
0.028; O
respectively, O
) O
in O
the O
population O
studied. O

Linoleic B-lipid
acid I-lipid
has O
been O
shown O
recently O
to O
inhibit O
the O
growth O
of O
CRC O
cells O
by O
mediating O
oxidative O
stress O
and O
mitochondrial O
dysfunction. O

There O
is O
no O
obvious O
trend O
in O
the O
changes O
of O
the O
Δ9/Δ11 O
isomers O
and O
neither O
do O
the O
changes O
correlate O
with O
relative O
isomeric O
composition O
in O
free O
FA B-lipid
18:1 I-lipid
(I O
_Δ9 O
/I O
_Δ11 O
 = 10.5 ± O

Chief O
among O
them O
are O
several O
GPLs O
that O
are O
believed O
to O
have O
biological O
significance O
in O
cancer O
physiology, O
including O
PC(32:1), B-lipid
PC(34:1), B-lipid
PS(38:5), B-lipid
PE(38:6), B-lipid
PC(32:3), B-lipid
and O
PC(34:2)._5 O
, O

Platelets, O
common O
sources O
of O
MVs, O
have O
been O
shown O
to O
externalize O
PS(18:0_18:1) B-lipid
and O
PS(18:0_20:4) B-lipid
from O
the O
inner O
to O
outer O
membrane O
when O
activated O
by O
thrombin. O

In O
contrast, O
ceramide O
(Cer) O
Cer(d18:1/21:0) B-lipid
and O
Cer(d18:2/23:0), B-lipid
ursodeoxycholic O
acid O
(UDCA), O
and O
the O
ratios O
BCAA O
to O
ArAA, O
and O
BCAA O
to O
tyrosine O
(BTR) O
decreased O
along O
with O
the O
fibrosis O
stages O
of O
the O
studied O
patients O
(absolute O
PCC > 0.98). O

In O
a O
second O
example O
from O
human O
plasma O
extract, O
the O
elution O
profile O
of O
a O
phosphatidylcholine O
of O
sum O
composition O
PC B-lipid
32:2 I-lipid
is O
shown O
in O
. O

LPC O
profiling O
revealed O
statistically O
significant O
downregulation O
of O
LPC(16:0) B-lipid
in O
HCC O
relative O
to O
AML O
(P<0.001) O
and O
HV O
(P<0.05). O

While O
the O
sensitivity O
for O
glucose, O
galactose, O
and O
cysteine O
+ O
cystine O
was O
≥85%, O
that O
for O
nonanoic B-lipid
acid I-lipid
was O
79%. O

The O
ABCD2 O
+ O
LAA O
+ O
LysoPC(20:4) B-lipid
model O
showed O
the O
highest O
calibration O
(χ_2 O
3.58, O
p O
= O
0.309), O
whereas O
the O
ABCD2 O
+ O
LAA O
+ O
LysoPC(16:0) B-lipid
model O
showed O
the O
lowest O
calibration O
values O
(χ_2 O
17.33, O
p O

Indeed, O
4/20 O
HCC O
patients O
had O
inordinately O
high O
LPA(16:0) B-lipid
plasma O
levels O
and O
that O
LPA(16:0) B-lipid
strongly O
correlated O
with O
plasma O
AFP O
concentrations. O

Cholesterol B-lipid
esterification O
is O
regulated O
by O
lecithin–cholesterol O
acyltransferase O

In O
summary, O
TCDCA, O
GCA, O
and O
SM(d18:0/18:0), B-lipid
which O
rose O
very O
significantly O
along O
with O
the O
severity O
of O
liver O
fibrosis, O
were O
the O
metabolites O
that O
better O
discriminate O
between O
rapid O
and O
slow O
fibrosers O
in O
both, O
univariate O
and O
multivariate O
analyses O
(Fig. O

The O
underlying O
fatty O
acid O
signals O
were O
quantified O
by O
the O
peak O
intensities O
of O
the O
diacyl O
fragment O
ions O
normalized O
against O
the O
diacyl O
fragment O
ion O
signal O
of O
the O
pre-extraction O
spiked O
synthetic O
TAG B-lipid
17:0/17:0/17:0 I-lipid
standard O
and O
plasma O
volume. O

Pentadecanoic B-lipid
acid I-lipid
(C15:0) O
and O
heptadecanoic B-lipid
acid I-lipid
(C17:0) O
were O
evaluated O
in O
the O
GC-MS O
data O
in O
a O
targeted O
approach O
by O
assessing O
the O
response O
of O
their O
quantifier O
ions O
at O
known O
retention O
time O
normalised O
with O
the O
quantifier O
ion O
of O
internal O
standard. O

We O
believe O
it O
is O
reasonable O
to O
consider O
the O
use O
of O
interventions O
targeting O
the O
metabolism O
of O
LysoPC(P-15:0), B-lipid
PC(P-34:4), B-lipid
and O
PC(38:6) B-lipid
as O
a O
palliative O
treatment O
for O
patients O
with O
ascites. O

20-HETE B-lipid
induced O
cell O
proliferation O
and O
DNA O
synthesis O
in O
vascular O
smooth O
muscle O
and O
proximal O
tubule O
cell O
cultures O
as O
well O
as O
angiogenic O
effects O
by O
stimulating O
endothelial O
cell O
proliferation, O
which O
was O
accompanied O
by O
increased O
vascular O
endothelial O
growth O
factor O
(VEGF) O
expression O
and O
release O
(, O
, O
). O

Two O
critical O
pairs O
derived O
from O
AA, O
including O
HETEs O
(19-HETE O
and O
20-HETE) O
and O
EETs O
(11,12-EET O
and O
8,9-EET) B-lipid
were O
chosen O
to O
demonstrate O
the O
importance O
of O
selecting O
appropriate O
transitions. O

Other O
(unidentified) O
molecular O
species O
were O
calibrated O
with O
PC(17:0/0:0) B-lipid
for O
retention O
time O
< O
300 O
s, O
PC(17:0/17:0) B-lipid
for O
retention O
time O
between O
300 O
s O
and O
410 O
s, O
and O
TG(17:0/17:0/17:0) B-lipid
for O
higher O
retention O
times. O

The O
intra-run O
precisions O
at O
LLOQ O
level O
were O
2.7–3.4%CV O
and O
2.8–3.4%CV O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively. O

The O
poor O
selectivity O
issue O
is O
not O
limited O
to O
oxylipins O
derived O
from O
AA, O
those O
derived O
from O
DHA, O
such O
as O
14-HDoHE B-lipid
and O
10-HDoHE B-lipid
also O
exhibited O
identical O
retention O
on O
LC. O

c, O
d O
Comparisons O
of O
individual-to-individual O
variations O
based O
on O
c O
relative O
quantitation O
(I O
/I O
_IS O
) O
of O
PE B-lipid
16:0_18:1 I-lipid
and O
d O
relative O
isomer O
ratio O
(I O
_Δ9 O
/I O
_Δ11 O
) O
measurement O
of O
PE B-lipid
16:0_18:1 I-lipid
in O
normal O
and O
T2D O
plasma O
samples. O

Apo, O
apolipoprotein; O
CI, O
confidence O
interval; O
DHA, O
docosahexaenoic B-lipid
acid; I-lipid
FA, O
fatty O
acid; O
HOMA‐IR, O
homeostatic O
model O
assessment O
of O
insulin O
resistance; O
IDL, O
intermediate‐density O
lipoprotein; O
LDL, O
low‐density O
lipoprotein; O
MUFA, O
monounsaturated O
fatty O
acid; O
PUFA, O
polyunsaturated O
fatty O
acid; O
SFA, O
saturated O
fatty O
acid. O

Cholesterol B-lipid
oxidase O
converts O
sterols O
with O
a O
3β-hydroxy-5-ene O
function O
to O
3-oxo-4-ene O
analogues O
(Scheme O
2) O
and O
a O
3β-hydroxy-5α-hydrogen O
function O
to O
a O
3-oxo O
function. O

Palmitic B-lipid
acid I-lipid
trended O
upward O
in O
Q3-4, O
whereas O
linoleic O
and O
lignoceric O
acids O
trended O
lower. O

In O
addition, O
a O
decrease O
in O
the O
total O
level O
of O
LPI O
and O
marginally O
significant O
decreases O
in O
major O
PI O
species O
including O
PI38:4, B-lipid
36:2, O
36:3, O
34:2 O
were O
also O
observed O
in O
diabetic O
monkeys O
under O
fed O
conditions. O

In O
addition, O
especially, O
depletion O
of O
docosahexaenoic B-lipid
acid I-lipid
(C22:6) O
may O
influence O
on O
homeostasis O
of O
liver O
tissue, O
likely O
fibrosis O
progression. O

Cholesterol B-lipid
is O
an O
essential O
constituent O
of O
the O
plasma O
membrane O
and O
rigidifies O
it. O

15-HETE, B-lipid
a O
major O
AA O
metabolite, O
was O
also O
present O
at O
higher O
levels O
in O
the O
urine O
of O
young O
women. O

A O
predictive O
model O
(ZS) O
was O
then O
developed O
based O
on O
the O
concentrations O
of O
GNOE O
and O
MG B-lipid
(18:2), I-lipid
and O
achieved O
greater O
accuracy O
than O
the O
three O
individual O
metabolites O
mentioned O
above O
in O
the O
diagnosis O
of O
BAV O
for O
the O
validation O
group. O

We O
identified O
some O
metabolites O
that O
were O
not O
measured O
in O
GDM O
patients O
before, O
such O
as O
n-acetylaspartic O
acid, O
2,3,4-trihydroxybutyric O
acid, O
2-aminobutanoic B-lipid
acid, I-lipid
2-oxo-4-methylvaleric O
acid, O
4-aminobutanoic B-lipid
acid, I-lipid
aminomalonic O
acid, O
1-monooleoylglycerol, O
2-ethylhexanoic B-lipid
acid, I-lipid
mannose, O
maltose, O
threitol, O
threonic O
acid. O

An O
IS O
for O
each O
lipid O
class O
were O
selected O
for O
single-point O
calibrations O
of O
each O
target O
lipid O
species O
(LPC O
17:1, O
LPC B-lipid
17:1, I-lipid
LPE B-lipid
17:1, I-lipid
PC O
31:1(17:0/14:1), O
PC O
31:1(17:0/14:1), O
PC O
31:1(17:0/14:1), O
PE O
31:1(17:0/14:1), O
PE O
31:1(17:0/14:1), O
SM O
30:1(d18:1/12:0), O
ceramide O
15:1, O
CE O
15:0, O
DAG O
16:0(8:0/8:0), O
and O
TAG O
45:0(15:0/15:0/15:0) O
for O
LPC, O
plasmenyl O
LPC, O
LPE, O
PC, O
plasmenyl O
PC, O
plasmanyl O
PC, O
PE, O
plasmenyl O
PE, O
SM, O
ceramide, O
CE, O
DAG, O
and O
TAG O
class, O
respectively). O

In O
this O
study, O
the O
level O
of O
PC B-lipid
(15:0/16:0) I-lipid
was O
highest O
in O
the O
GP O
group, O
followed O
by O
BT O
and O
PP. O

Additionally, O
inhibition O
of O
the O
synthesis O
and O
actions O
of O
20-HETE B-lipid
with O
HET0016 O
and O
WIT002 O
(20-HETE O
antagonist) O
inhibits O
the O
proliferation O
of O
renal O
adenocarcinoma O
cells O
in O
vitro O
and O
the O
growth O
of O
kidney O
cancer O
tumors O
in O
an O
animal O
model O
in O
vivo O
. O

Higher O
levels O
of O
the O
12-LOX O
products O
12-HETE B-lipid
and O
14-HDHA O
in O
serum O
are O
likely O
due O
to O
activation O
of O
platelet-derived O
12-LOX O
during O
the O
clotting O
cascade. O

(b) O
Negative O
correlation O
of O
serum O
sphingosine O
level O
at O
the O
basal O
status O
with O
(b1) O
serum O
SM B-lipid
(d18:0/16:0), I-lipid
(b2) O
with O
serum O
SM O
(d18:0/18), O
(b3) O
with O
serum O
SM B-lipid
(d18:0/18:1), I-lipid
(b4) O
with O
serum O
LysoSM O
before O
the O
ASA-BPT. O

The O
levels O
of O
SM(36:3) B-lipid
and O
PC(40:7) B-lipid
were O
increased O
at O
w16 O
and O
declined O
to O
the O
levels O
observed O
before O
intervention O
(w0) O
at O
w28 O
for O
the O
TFA O
group, O
whereas O
there O
was O
no O
change O
for O
the O
CTR O
group. O

(P O
= O
0.011), O
uric O
acid O
(P O
= O
0.02), O
l-aspartyl-l-phenylalanine O
(P O
= O
0.0002), O
and O
lysoPCs O
containing O
C18:1 O
(P O
= O
0.037), O
C18:2 O
(P O
= O
0.045), O
C20:1 O
(P O
= O
0.008), O
and O
C20:4 O
(P O
= O
0.03), O
showed O
a O
significant O
increase O
during O
12 O
weeks O
of O
peptide O
intervention, O
whereas O
20 O
metabolites, O
that O
is, O
l-proline O
(P O
= O
0.003), O
valine O
(P O
= O
0.042), O
l-leucine/isoleucine O
(P O
= O
0.048), O
hypoxanthine O
(P O
= O
0.036), O
glutamine O
(P O
= O
0.028), O
l-methionine O
(P O
= O
0.039), O
phenylpyruvic O
acid O
(P O
= O
0.041), O
propionylcarnitine O
(P O
= O
0.05), O
butyrylcarnitine O
(P O
= O
0.05), O
l-hexanoylcarnitine O
(P O
= O
0.06), O
l-octanoylcarnitine O
(P O
= O
0.014), O
palmiotylcarnitine O
(P O
= O
0.034), O
linoleylcarnitine O
(P O
= O
0.02), O
and O
PCs O
containing O
C14:0 O
(P O
= O
0.045), O
PC16:0 B-lipid
(P O
= O
0.02), O
C15:0 O
(P O
= O
0.012), O
C16:0 O
(P O
= O
0.018), O
C17:1 O
(P O
= O
0.02), O
C18:0 O
(P O
= O
0.038), O
and O
C22:0 O
(P O
= O
0.029) O
showed O
decreased O
levels. O

Several O
PUFA O
metabolites O
originating O
from O
various O
LOX O
pathways, O
in O
particular O
5-HETE, B-lipid
8-HETE, B-lipid
12-HETE, B-lipid
15-HETE, B-lipid
HXA_3 O
, O
9-HODE, O
13-HODE, B-lipid
13-oxoODE, O
5-oxoETE, O
15-oxoETE, O
LXA_4 O
, O
5-HEPE, O
12-HEPE, B-lipid
8-HEPE, O
4-HDHA, O
10-HDHA, O
14-HDHA O
and O
17-HDHA O
were O
increased O
in O
AgP O
patient O
samples O
compared O
with O
healthy O
controls. O

Palmitic B-lipid
acid I-lipid
(16:0) O
levels O
were O
positively O
associated O
with O
inflammatory O
monocyte O
(CD14_+ O
CD16_+ O
) O
surface O
expression O
of O
the O
innate O
immune O
receptor, O
TLR4, O
and O
myristic O
acid O
(14:0) O
was O
positively O
associated O
with O
levels O
of O
CD36, O
a O
scavenger O
receptor O
involved O
in O
immune O
signaling O
and O
lipid O
uptake. O

The O
absolute O
concentration O
(ng/mL) O
of O
each O
PC O
was O
calculated O
based O
on O
the O
peak O
area O
of O
the O
PC O
identified O
in O
the O
sample O
and O
the O
peak O
area O
of O
the O
internal O
standard O
of O
PC B-lipid
(15:0/18:1) I-lipid
corresponding O
to O
the O
sample O
(the O
formula O
was O
shown O
in O
Figure _S1 O
). O

The O
CerS2 O
and O
CerS4 O
are O
responsible O
for O
production O
of O
Cer(22:0) B-lipid
and O
Cer(24:0). B-lipid

In O
a O
single O
sample O
Jager O
et O
al. O
found O
concentrations O
of O
8.7 O
ng/mL O
JWH-018 O
5-hydroxypentyl, O
0.89 O
ng/mL O
JWH-018 O
pentanoic B-lipid
acid, I-lipid
0.55 O
ng/mL O
JWH-073 O
butanoic B-lipid
acid, I-lipid
0.67 O
ng/mL O
JWH-073 O
hydroxybutyl, O
and O
0.25 O
ng/mL O
JWH-250 O
pentanoic B-lipid
acid. I-lipid

Proportional O
amounts O
of O
LPC(16:0) B-lipid
were O
positively O
associated O
with O
serum O
levels O
of O
ICAM1, O
and O
LPC(18:2) B-lipid
was O
negatively O
associated O
with O
ICAM1. O

Two O
sample O
preparation O
methodologies O
were O
used O
and O
validated O
for O
the O
analysis O
of O
AA, O
12-HETE, B-lipid
15-HETE, B-lipid
20-HETE, B-lipid
11(12)-DiHETE O
and O
14(15)-DiHETE O
in O
plasma. O

Concentrating O
on O
the O
direct O
association O
of O
the O
serum O
metabolite O
profiles O
of O
BC O
and O
the O
histopathology O
of O
bladder O
tissue, O
a O
composite O
panel O
of O
potential O
biomarkers O
including O
inosine, O
AFMK O
and O
PS(O-18:0/0:0) B-lipid
was O
identified O
as O
a O
diagnostic O
tool, O
which O
could O
precisely O
distinguish O
not O
only O
between O
HG O
BC O
and O
LG O
BC O
but O
also O
between O
LG O
BC O
and O
healthy O
control. O

Lipid O
peroxidation, O
quantitation, O
4-hydroxy-2-nonenal, B-lipid
4-oxo-2-nonenal, B-lipid
mass O
spectrometry, O
smoking O

ROC O
curves O
for O
the O
combination O
of O
2-methoxy-4-methylphenol, O
3-aminosalicylic O
acid, O
3-hydroxyanthranilic O
acid O
and O
4-hydroxypentenoic B-lipid
acid. I-lipid

To O
this, O
750 µl O
methyl O
tert-butyl O
ether O
(MTBE) O
was O
added, O
along O
with O
150 µl O
of O
internal O
standard O
mix, O
containing O
the O
following O
six O
internal O
standards: O
1,2-di-o-octadecyl-sn-glycero-3-phosphocholine O
(0.6 µM), O
1,2-di-O-phytanyl-sn-glycero-3-phosphoethanolamine O
(1.2 µM), O
C8-ceramide O
(0.6 µM), O
N-heptadecanoyl-D-erythro-sphingosylphosporylcholine O
(0.6 µM), O
undecanoic B-lipid
acid I-lipid
(0.6 µM), O
and O
trilaurin O
(0.6 µM). O

Glucose O
(A), O
unsaturated O
FA B-lipid
18:1 I-lipid
(B) O
and O
18:2 O
(C), O
shown O
as O
carbon: O
double O
bond O
ratio. O

The O
identity O
of O
our O
SM(d18:2/18:1) B-lipid
marker O
needs O
to O
be O
finally O
proven O
in O
separate O
studies, O
and O
if O
the O
assignment O
is O
correct O
the O
biological O
and O
especially O
neurological O
consequence O
of O
changing O
the O
usual O
cis O
-Δ3-sphingosines O
by O
an O
aberrant O
backbone O
must O
be O
elucidated. O

Our O
findings O
described O
that O
among O
all O
metabolites O
of O
the O
platelet O
activation/aggregation O
pathway O
analysed O
in O
a O
group O
of O
men O
with O
unstable O
carotid O
plaque O
vs O
a O
healthy O
control O
group, O
the O
only O
metabolite O
which O
showed O
the O
highest O
and O
most O
significant O
levels O
is O
20-HETE. B-lipid

PC(32:0) B-lipid
and O
PC(36:0) B-lipid
for O
which O
CLR O
estimated O
considerably O
higher; O
than O
Biocrates O
and O
Quehenberger O
et O
al.; O
and O
3) O
the O
quantified O
concentration O
of O
PC(40:2) B-lipid
by O
Quehenberger O
et O
al. O

LTB4 B-lipid
has O
a O
receptor O
with O
high O
specificity, O
B O
leukotriene O
receptor O
1 O
(BLT1), O
expressed O
exclusively O
in O
inflammatory O
cells O
such O
as O
neutrophils, O
macrophages O
and O
eosinophils. O

The O
predictive O
capacities O
of O
GNOE, O
MG B-lipid
(18:2), I-lipid
PE B-lipid
(18:2) I-lipid
and O
ZS O
were O
further O
evaluated O
by O
the O
use O
of O
a O
validation O
group O
that O
also O
consisted O
of O
30 O
BAV O
patients O
and O
20 O
healthy O
adults. O

For O
example, O
the O
decrease O
in O
the O
fatty O
acids O
18:3 O
and O
20:3 O
with O
fish O
oil O
supplementation O
as O
determined O
by O
GC-MS O
is O
consistent O
with O
the O
decrease O
of O
PC(36:3) B-lipid
and O
PC(38:3) B-lipid
if O
one O
assumes O
that O
one O
of O
the O
fatty O
acids O
in O
these O
species O
is O
the O
highly O
abundant O
palmitate O
(16:0—Fig. O

Among O
these, O
six O
phosphotidylcholines, O
PC B-lipid
(34:2), I-lipid
PC B-lipid
(34:1), I-lipid
PC B-lipid
(36:3), I-lipid
PC B-lipid
(36:2), I-lipid
PC B-lipid
(32:0), I-lipid
and O
PC B-lipid
(38:4) I-lipid
and O
one O
sphingomyelin, O
SM B-lipid
(16:0) I-lipid
were O
altered O
in O
both O
MF O
tissues O
and O
sera. O

The O
urinary O
excretion O
of O
20-HETE B-lipid
was O
significantly O
lower O
in O
subjects O
with O
renovascular O
disease O
(median: O
12.9 O
μ O
g/g O
of O
creatinine; O
range: O
4.4 O
to O
24.9 O
μ O
g/g O
of O
creatinine) O
than O
in O
control O
subjects O
(median: O
31.0 O
μ O
g/g O
of O
creatinine; O
range: O
11.9 O
to O
102.8 O
μ O
g/g O
of O
creatinine; O
P O
<0.01) O
and O
essential O
hypertensive O
subjects O
(median: O
35.9 O
μ O
g/g O
of O
creatinine; O
range: O
14.0 O
to O
72.5 O
μ O
g/g O
of O
creatinine; O
P O
<0.05). O

Abbreviations: O
MSA: O
multiple O
system O
atrophy; O
AUC: O
area O
under O
the O
curve; O
FA: O
fatty O
acid; O
LysoPC(16:0): B-lipid
lysophosphatidylcholine O
(16:0); O
DHEAS: O
dehydroisoandrosterone O
3-sulfate O

Moreover, O
we O
found O
statistically O
significant O
positive O
correlations O
between O
the O
Lactate O
Dehydrogenase O
levels O
and O
the O
following O
metabolites: O
Octadecenoylcarnitine O
(r O
= O
0.41, O
p O
= O
0.044), O
Docosahexaenoic B-lipid
Acid I-lipid
(r O
= O
0.45, O
p O
= O
0.023), O
Symmetric O
dimethylarginine O
(r O
= O
0.46, O
p O
= O
0.022), O
and O
significant O
negative O
correlations O
with O
Valine O
(r O
= O
−0.41, O
p O
= O
0.043) O
and O
tripentadecanoate O
TG15 O
(r O
= O
−0.43, O
p O
= O
0.030) O
levels, O
among O
PC O
patients. O

Serum O
total O
cholesterol O
and O
triglycerides O
were O
measured O
by O
an O
enzymatic O
colorimetric O
method O
with O
commercial O
kits O
(Monotest O
Cholesterol B-lipid
and O
Triglyceride O
GPO-PAP, O
Boehringen O
Mannheim O
GmbH O
Diagnostica) O
using O
an O
automated O
instrument O
(Kone O
Specific O
Clinical O
Analyzer, O
Kone O
Ltd, O
Espoo, O
Finland). O

As O
shown O
in O
, O
serum O
levels O
of O
lysoPC(18:2), B-lipid
PhePhe, O
uridine, O
taurine, O
L-threonine, O
and O
(R)-3-Hydroxy-hexadecanoic B-lipid
acid I-lipid
were O
significantly O
correlated O
with O
activity O
scores O
(all O
p<0.05) O
in O
AOSD O
patients. O

In O
this O
study, O
the O
LacCer B-lipid
(d18:1/16:0) I-lipid
level O
was O
highest O
in O
the O
BT O
group, O
followed O
by O
GP O
and O
being O
lowest O
in O
PP. O

15-HETE B-lipid
was O
recently O
shown O
to O
promote O
HCC O
growth O
and O
metastasis O
through O
the O
phosphoinositide O
3-kinase/protein O
kinase O
B/heat O
shock O
protein O
90 O
(PI3K/Akt/HSP90) O
pathway. O

Our O
previous O
studies O
have O
shown O
that O
DAG B-lipid
34:2 I-lipid
is O
comprised O
mainly O
of O
DAG B-lipid
16:0/18:2 I-lipid
while O
DAG B-lipid
36:2 I-lipid
is O
66% O
DAG B-lipid
18:1/18:1 I-lipid
and O
33% O
DAG B-lipid
18:0/18:2, I-lipid
with O
no O
differences O
in O
fatty O
acid O
composition O
of O
these O
DAGs O
between O
aged-matched O
control, O
MCI O
and O
LOAD O
subjects O
. O

Intra- O
and O
inter-assay O
accuracy O
and O
precision O
of O
Cer(22:0) B-lipid
and O
Cer(24:0) B-lipid

522.39 O
Da], O
and O
phosphatidylcholines: O
PC(34:1) B-lipid
[m O
/z O
= O
760.63 O
Da] O
and O
PC(36:1) B-lipid

In O
a O
mass O
spectrometry-based O
study, O
plasma O
LysoPC(16:0) B-lipid
was O
more O
significantly O
decreased O
in O
lung O
cancer O
patients O
than O
in O
healthy O
controls. O

Elevated O
serum O
levels O
of O
eicosapentaenoic B-lipid
acid I-lipid
observed O
in O
the O
current O
work O
may O
similarly O
reflect O
its O
restricted O
conversion O
to O
anti-inflammatory O
DHA-derived O
lipid O
mediators O
in O
obese O
NASH. O

Panel O
a: O
PE(16:0/16:1), B-lipid
PE(16:0/18:3), B-lipid
PE(16:0/18:2), B-lipid
PE(18:0/16:0), B-lipid
PE(17:0/18:2), B-lipid
PE(18:0/17:1), B-lipid
PE(17:0/18:1), B-lipid
PE(20:5/16:0), B-lipid
PE(18:0/18:1), B-lipid
PE(18:1/20:4), B-lipid
PE(18:0/20:3), B-lipid
PC(15:0/18:1, O
PC(16:1/20:5), O
and O
PC(18:0/20:1); O
Panel O
b: O
PE(16:0/18:3), O
PE(18:0/16:0), O
PE(17:0/18:2), B-lipid
PE(17:0/18:1), B-lipid
PE(18:2/18:2), B-lipid
PE(18:1/18:2), B-lipid
PE(18:0/18:1), B-lipid
PE(18:1/20:4), B-lipid
PC(16:1/20:5), B-lipid
and O
PC(18:0/20:1); B-lipid
Panel O
c: O
PE(18:0/18:2) B-lipid
and O
PC(15:0/18:1). B-lipid

They O
fell O
into O
six O
lipid O
categories, O
comprising O
two O
lysophospholipids O
(LPC(20:2) O
and O
LPE(18:2); O
lowered O
2.8- O
to O
3.2-fold), O
four O
triglycerides O
(TG(51:8), O
TG(52:8), O
TG(53:8), O
and O
TG(53:9); O
lowered O
2.1- O
to O
2.7-fold), O
13 O
phospholipids O
(PC(32:0), O
PC(36:2), O
two O
PC(36:3)s, O
PC(36:4), O
PC(36:5), O
PC(38:3), B-lipid
PC(40:7), B-lipid
PC(40:8), B-lipid
PC(P-36:4), B-lipid
PE(40:6), B-lipid
PE(44:10), B-lipid
and O
PS(36:2); B-lipid
lowered O
1.4- O
to O
29.5-fold), O
14 O
sphingolipids O
(SM(18:1/12:0), O
SM(18:1/14:0), O
SM(18:1/20:0), O
two O
SM(18:1/22:1)s, O
SM(18:1/23:0), O
SM(18:1/24:1), B-lipid
SM(18:0/12:0), B-lipid
SM(18:0/22:0), B-lipid
SM(18:0/22:1), B-lipid
SM(18:0/24:0), B-lipid
two O
SM(18:0/24:1)s, O
and O
Cer(18:1/24:1); B-lipid
lowered O
1.3- O
to O
4.8-fold), O
four O
cholesterol O
esters O
(cholesterol O
3-O O
-sulfate, O
CE(18:2), O
CE(18:3), O
and O
CE(20:3); O
lowered O
1.4- O
to O
2.1-fold), O
and O
coenzyme O
Q10 O
(CoQ10; O
lowered O
1.6-fold). O

LC-MRM-MS O
Chromatograms O
for O
19-HETE O
and O
20-HETE B-lipid
at O
three O
different O
ratios O
in O
neat O
solution. O

Hexanal, B-lipid
as O
well O
as O
other O
aldehydes, O
for O
instance, O
has O
been O
already O
reported O
by O
several O
authors O
as O
discriminant O
metabolites O
for O
LC. O

The O
pairplot O
demonstrates O
the O
abundance O
of O
the O
two O
monohydroxy O
fatty O
acids O
12-HEPE O
and O
5-HEPE B-lipid
at O
baseline O
levels O
before O
the O
surgery O
(T0) O
and O
24 O

Of O
note, O
LysoPC O
with O
acyl-chain O
of O
docosahexaenoic B-lipid
acid I-lipid
(C22:5), O
a O
component O
of O
the O
biomarker O
panel, O
has O
also O
been O
identified O
as O
a O
marker O
of O
ageing O
and O
hepatocarcinogenesis. O

PS B-lipid
(12:0/12:0), I-lipid
phosphatidic O
acid O
(PA) O
(12:0/12:0); O
cardiolipin O
(CL) O
(14:0/14:0/14:0/14:0); O
sphingomyelin O
(SM) O
(d18:1/12:0); O
ceramide O
(Cer) O
(d18:1/12:0); O
glycosylceramide O
(CerG1) O
(d18:1/12:0); O
sulfatide O
(ST) O
(d18:1/12:0); O
diacylglycerol O
(DG) O
(12:0/12:0) O
(Avanti O
Polar O
Lipids, O
Alabaster, O
AL, O
USA), O
cholesterolester O
(ChE) O
(12:0); O
and O
triacylglycerol O
(TG)(16:0/16:0/16:0-13C3) O
(Larodan O
Fine O
Chemicals, O
Solna, O
Sweden). O

The O
authors O
suggested O
that O
2-methylbutanal B-lipid
as O
a O
potentially O
useful O
biomarker O
to O
identify O
smoking O
habits. O

12-HETE B-lipid
in O
veterans O
with O
GWI O
was O
by O
decreased O
by O
63% O
(Z O
= O
-0.84, O
), O
and O
contributed O
4% O
of O
the O
metabolic O
impact O
(, O
VIP O
= O
2.2). O

A O
Kruskal-Wallis O
test O
of O
the O
individual O
time-points O
for O
each O
of O
the O
selected O
candidate O
markers O
revealed O
that O
most O
of O
them O
can O
be O
detected O
postprandially O
at O
more O
than O
one O
time-point O
between O
1 O
and O
6 O
h O
(lactose, O
galactose, O
galactitol, O
galactonate, O
galactono-1,5-lactone, O
methionine, O
proline, O
3-phenyllactic O
acid, O
dodecanoic B-lipid
acid, I-lipid
linoleic O
acid, O
γ-tocopherol, O
maltol, O
sucrose, O
unknown O
S13, O
unknown O
S27), O
their O
presence O
in O
serum O
being O
no O
longer O
detected O
at O
24 O
h O
(Table O
S3). O

Only O
4 O
SPs, O
SM B-lipid
d16:1/18:0 I-lipid
and O
SM B-lipid
d18:1/18:0 I-lipid
and O
their O
metabolic O
precursors, O
Cer B-lipid
d16:1/18:0 I-lipid
and O
Cer B-lipid
d18:1/18:0, I-lipid
remained O
significant O
after O
adjustment O
for O
BMI, O
and O
when O
HbA1c O
was O
added O
to O
the O
model, O
only O
the O
2 O
SMs O
remained O
independently O
associated O
with O
T2DM O
incidence. O

47 O
target O
metabolites O
(L-Tyrosine, O
L-Phenylalanine, O
L-Threonine, O
L-(+)-Lactic O
acid, O
L-Valine, O
L-Leucine, O
L-Proline, O
Betaine, O
Palmitic B-lipid
acid, I-lipid
Stearic O
acid, O
Glycine, O
(±)-a-Tocopherol, O
β-Sitoseterol, O
L-Tryptophan, O
DL-glyceraldehyde, O
Glycocholic O
acid, O
oleic O
acid, O
eicosanoic B-lipid
acid, I-lipid
hexanoic B-lipid
acid, I-lipid
Heptanoic B-lipid
acid, I-lipid
nonanoic B-lipid
acid, I-lipid
Galactose, O
Sucrose, O
Sorbitol, O
myoinositol, O
Fructose, O
Cellobiose, O
Urea, O
Isoleucine, O
Alanine, O
citric O
acid, O
Azelaic O
acid, O
Aspartic O
acid, O
4-Hydroxybenzoic O
acid, O
Pimelic O
acid, O
L-Serine, O
Hypoxanthine, O
D-Homoserine, O
Uric O
acid, O
Trimethylamine O
oxide, O
Pentanedioic B-lipid
acid, I-lipid
Allantoin, O
Linoleic B-lipid
acid, I-lipid
Citrulline, O
Oxaloacetic O
acid, O
and O
Sorbose O
andα-ketoglutaric O
acid) O
were O
selected O
from O
previous O
studies O
that O
reported O
new O
biomarkers O
or O
important O
metabolites O
for O
EH O
and O
related O
cardiovascular O
diseases. O

Maximum O
concentrations O
were O
845 O
ng/mL O
for O
JWH-018 O
5-hydroxypentyl, O
284 O
ng/mL O
for O
JWH-018 O
pentanoic B-lipid
acid, I-lipid
315 O
ng/mL O
for O
JWH-073 O
butanoic B-lipid
acid, I-lipid
10 O
ng/mL O
for O
JWH-018 O
6-hydroxyindole, O
and O
6.2 O
ng/mL O
for O
JWH-073 O
4-hydroxybutyl. O

The O
collision O
activated O
dissociation O
product O
ion O
spectrum O
of O
the O
[M+H]_+ O
ion O
of O
Cer(22:0) B-lipid
at O
m/z O
622 O
and O
proposed O
structures O
of O
the O
fragment O
ions O
are O
shown O
in O
. O

In O
a O
previous O
study, O
a O
shotgun O
lipid O
analysis O
incorporated O
with O
the O
PB O
reaction O
revealed O
significant O
changes O
in O
the O
C=C O
isomer O
compositions O
of O
C18:1 O
(Δ9/Δ11) O
for O
PC B-lipid
18:0_18:1 I-lipid
and O
PC B-lipid
18:1_18:1. I-lipid

PC O
cleavage O
can O
also O
be O
performed O
by O
PLD O
to O
generate O
PA, O
such O
as O
the O
PA B-lipid
(32:0) I-lipid
and O
PA(P-31:1) B-lipid
found O
in O
this O
study. O

On O
the O
other O
hand, O
we O
observed O
low O
levels O
of O
PC B-lipid
(O-16:0/0:0), I-lipid
LPC B-lipid
(16:0), I-lipid
LPC B-lipid
(18:0) I-lipid
and O
LPE B-lipid
(20:0) I-lipid
and O
high O
levels O
of O
PC B-lipid
(34:2), I-lipid
LPC O

The O
transitions O
monitored O
were: O
337.2>207.1 O
and O
337.2>319.3 O
for O
14(15)-DiHET O
(rt: O
5.4 O
min), O
337.2>167.0 O
and O
337.2>319.3 O
for O
11(12)-DiHET O
(rt: O
5.7 O
min), O
319.2>275.3, O
319.2>301.3 O
and O
319.2>289.2 O
for O
20-HETE B-lipid
(rt: O
6.6 O
min), O
319.2>219.2, O
319.2>301.3 O
and O
319.2>175.0 O
for O
15-HETE B-lipid
(rt: O
7.6 O
min), O
319.2>179.2, O
319.2>301.3 O
and O
319.2>257.2 O
for O
12-HETE B-lipid
(rt: O
8.2 O
min), O
303.2>259.2, O
303.2>205.1 O
and O
303.2>58.7 O
for O
AA O
(rt: O
15.1 O
min) O
and O
311.3>267.3 O
for O
AA-d8 O
(rt: O
14.9 O
min). O

Thus, O
relatively O
low O
leukocyte O
number, O
which O
may O
be O
associated O
with O
low O
levels O
of O
5-HETE B-lipid
and O
leukotriene O
B_4 O
, O
may O
lead O
to O
an O
improper O
inflammatory/immune O
function O
against O
future O
LC O
progression. O

As O
we O
were O
able O
to O
detect O
slightly O
higher O
levels O
of O
the O
COX-2 O
byproducts, O
15-HETE, B-lipid
13-HDHA, O
and O
17-HDHA, O
in O
individuals O
under O
statin O
treatment O
compared O
with O
untreated O
or O
ASA-treated O
subjects, O
there O
could O
be O
a O
combined O
effect O
of O
statin O
treatment O
to O
induce O
COX-2 O
expression O
and O
activation O
by O
S-nitrosylation O
leading O
to O
increased O
formation O
of O
15-HETE, B-lipid
13-HDHA, O
and O
17-HDHA O
(, O
, O
). O

Two O
metabolites, O
LPI B-lipid
(16:1) I-lipid
and O
dihomo-γ O
-linolenic O
acid, O
showed O
independent O
associations O
with O
incident O
type O
2 O
diabetes O
and O
significantly O
enhanced O
the O
risk O
prediction. O

Of O
these, O
the O
following O
four O
metabolites O
were O
finally O
selected O
as O
biomarker O
candidates O
by O
cross-validation: O
nonanoic B-lipid
acid, I-lipid
glucose, O
galactose, O
and O
cysteine O
+ O
cystine. O

The O
NP O
group O
showed O
an O
increased O
abundance O
in O
saturated O
fatty O
acids, O
myristic O
acid, O
nonanoic B-lipid
acid, I-lipid
palmitic O
acid, O
as O
well O
as O
in O
unsaturated O
fatty O
acids, O
gondoic O
acid, O
linoleic O
acid, O
oleic O
acid O
and O
arachidonic O
acid. O

Specifically, O
higher O
abundances O
of O
sugars O
and O
sugar O
alcohols, O
such O
as O
fructose, O
iditol, O
sedoheptulose, O
maltose, O
glycerol, O
galactosamine, O
and O
fatty O
acids, O
such O
as O
9, O
12-octadecanoic O
acid, O
oleic O
acid, O
hexanedioic B-lipid
acid, I-lipid
and O
pentanedioic B-lipid
acid, I-lipid
were O
observed O
in O
the O
H O
group. O

The O
levels O
of O
10-hydroxyldocosahexaenoic O
acid O
(HDoHE), O
12- O
hydroxyeicosapentaenoic O
acid O
(HEPE), O
and O
14-HDoHE B-lipid
were O
significantly O
higher O
in O
female O
urine. O

g O
docosahexaenoic B-lipid
acid I-lipid
(DHA)). O

The O
only O
PC O
lipid O
that O
is O
statistically O
significant O
and O
increased O
in O
fatal O
(F) O
vs. O
control O
(C) O
is O
PC(16:0/16:0). B-lipid

The O
relative O
amounts O
of O
LysoPC(16:0) B-lipid
and O
LysoPC(20:4(5Z,8Z,11Z,14Z)) B-lipid
were O
significantly O
lower O
in O
the O
PC, O
BTC, O
CRC, O
and O
OVC O
groups O
than O
in O
the O
control O
group O
(Fig. O
, O
Supporting O
Information O
Table O
4). O

For O
instance, O
C=C O
isomer O
compositional O
analysis O
revealed O
that O
PE B-lipid
34:1 I-lipid
consisted O
of O
two O
C=C O
location O
isomers, O
PE O
16:0_18:1(Δ9) O
and O
PE O
16:0_18:1(Δ11) O

Eleven O
metabolites O
(5-aminopentanoic O
acid, I-lipid
adenosine, O
betaine, O
carnitine, O
creatinine, O
deoxyguanosine, O
D-glutamic O
acid, O
glycerophosphocholine, O
L-valine, O
n-pentadecylamine, O
and O
taurine) O
were O
significantly O
increased O
in O
the O
AF O
group O
relative O
to O
the O
levels O
in O
the O
non-AF O
group, O
whereas O
the O
13 O
remaining O
metabolites O
(butyrylcarnitine, O
choline, O
dimethylglycine, O
guanosine, O
hypoxanthine, O
L-acetylcarnitine, O
L-alanine/sarcosine, O
L-alpha-aminobutyric O
acid, O
L-arginine, O
L-histidine, O
L-proline, O
niacinamide, O
and O
pantothenic O
acid) O
were O
all O
decreased O
(Supplementary O
Table _S1 O
). O

As O
shown O
in O
Table O
, O
the O
7 O
differentially O
expressed O
lipids O
are O
SM B-lipid
(16:0), I-lipid
PC B-lipid
(32:0), I-lipid
PC B-lipid
(34:2), I-lipid
PC B-lipid
(34:1), I-lipid
PC B-lipid
(36:3), I-lipid
PC B-lipid
(36:2) I-lipid
and O
PC B-lipid
(38:4). I-lipid

For O
instance, O
17 O
metabolites O
that O
potentially O
participate O
in O
Asp O
metabolism, O
ammonia O
recycling, O
protein O
biosynthesis, O
and O
Trp O
metabolism, O
which O
supports O
the O
environment O
needed O
for O
tumorigenesis O
(Figure O
B), O
were O
only O
quantified O
in O
the O
CRC O
group, O
i.e., O
Lys, O
heptanedioic B-lipid
acid I-lipid
(a O
precursor O
of O
Lys), O
norvaline, O
and O
several O
amino O
acid O
and O
organic O
acid O
derivatives O
(Supplementary O
Table O
). O

(A) O
Scores O
plot O
from O
OPLS O
multivariate O
analysis, O
cross-validated O
score O
plot O
resulting O
from O
OPLS O
modeling O
of O
Total O
Blood O
Cholesterol. B-lipid

Finally, O
in O
contrast O
to O
the O
AA O
canonical O
eicosanoid O
cascade, O
leading O
to O
the O
metabolites O
discussed O
above, O
data O
from O
the O
parallel O
pathway O
starting O
with O
eicosapentaenoic B-lipid
acid I-lipid
(EPA; O
20:5n-3) O
was O
also O
collected O
(Supplemental O
Fig. O
11C). O

Out O
of O
the O
62 O
serum O
metabolites O
identified O
in O
this O
study, O
48 O
of O
them O
were O
previously O
identified O
in O
human O
serum O
by O
NMR._, O
However, O
the O
other O
14 O
metabolites O
(1-methyluric O
acid, O
3-hydroxypropionic B-lipid
acid, I-lipid
alpha-hydroxyisobutyric O
acid, O
glyceric O
acid, O
glycerophosphocholine, O
ethanolamine, O
citrulline, O
hypotaurine, O
malate, O
trigonelline, O
taurine, O
valeric O
acid, O
beta-alanine, O
trans-4-hydroxyproline) O
have O
been O
identified O
here O
for O
the O
first O
time O
by O
using O
NMR O
alone. O

Pham O
et O
al. O
demonstrated O
monitoring O
of O
relative O
compositions O
of O
the O
same O
four O
isomers O
of O
PC B-lipid
16:0_18:1 I-lipid
individually O
from O
MS/MS O
experiments O
containing O
different O
sequences O
of O
OzID O
and O
CID. O

Two O
LMIs O
(496.3 m O
/z O
, O
retention O
time O
(RT) O
of O
18.9 min O
a O
and O
544.3 m O
/z O
, O
RT O
of O
18.3 min O
b O
were O
identified O
as O
LysoPC(16,0) O
and O
LysoPC(20:4(5Z,8Z,11Z,14Z)) B-lipid
according O
to O
the O
tandem O
mass O
spectrometry O
(MS/MS) O
patterns O
of O
serum O
samples O
of O
BTC O
patients O
Amounts O
of O
LysoPC(16:0) B-lipid
and O
LysoPC(20:4(5Z,8Z,11Z,14Z)) B-lipid
in O
the O
serum O
of O
PC O
and O
BTC O
patients. O

PC(18:1/20:3) B-lipid
and O
PC(18:1/22:5) B-lipid
are O
identified O
with O
two O
orthogonal O
data; O
retention O
time O
and O
spectral O
information. O

Representative O
MRM O
chromatogram O
of O
15-HETE, B-lipid
PGE_2 O
and O
RvD1 O
from O
patients O
with O
less O
active O
MS O
(black O
line) O
and O
with O
highly O
active O
MS O
(red O
line). O

We O
also O
used O
Mass O
Hunter O
Quantitative O
Analysis O
B.07.00 O
to O
quantify O
the O
15-HETE B-lipid
in O
which O
the O
deuterated O
internal O
standard O
15-HETE-d8 O
(Cayman O
Chemical) O
was O
used. O

Moreover, O
myristic O
acid, O
palmitic O
acid, O
linoleic O
acid, O
EPA, O
LPA B-lipid
(18:1), I-lipid
glycolic O
acid, O
lysoPC O
(22:6), O
and O
succinylacetone O
were O
emerged O
as O
independent O
variables O
influencing O
the O
incidence O
of O
LC. O

More O
recent O
studies O
by O
Guo O
et O
al. O
reported O
that O
HETE0016, O
a O
selective O
inhibitor O
of O
CYP4A/F O
enzymes O
(, O
) O
inhibited O
the O
formation O
of O
20-HETE B-lipid
resulting O
in O
suppression O
of O
both O
9L O
gliosarcoma O
and O
U251 O
glioma O
cell O
proliferation O
and O
tumor O
growth O
(, O
). O

Cer(d18:1/18:0), B-lipid
its O
precursor O
Cer(d18:0/18:0), B-lipid
and O
Cer(d18:1/22:0) B-lipid
were O
also O
higher. O

Considering O
the O
associations O
between O
PC O
and O
SM O
as O
well O
as O
GPCe O
and O
SM O
species, O
only O
SM B-lipid
22:3 I-lipid
did O
not O
correlate O
with O
most O
PC O
and O
GPCe O
species. O

**PE(18:2(9Z,12Z)/0:0): O
1-(9Z,12Z-Octadecadienoyl)-glycero-3-phosphoethanolamine; O
PC B-lipid
(18:1(9Z)/0:0): I-lipid
1-(9Z)-Octadecenoyl-sn-glycero-3-phosphocholine. O

The O
strongest O
positive O
correlator O
with O
the O
measured O
ex O
vivo O
VCAM-1 O
surface O
expression O
was O
Cluster O
1, O
which O
consisted O
predominantly O
of O
EPA O
and O
esterified O
EPA-derived O
metabolites O
(17,18-EpETE, O
9-HEPE, B-lipid
15-HEPE, B-lipid
5-HEPE). O

Heptadecanoic B-lipid
acid I-lipid
(C17:0) O
was O
used O
as O
an O
internal O
standard, O
and O
20 O
µL O
of O
the O
C17:0 O
(2 O
mg/mL O
in O
methanol) O
was O
also O
added. O

The O
identified O
molecular O
species O
were O
quantified O
by O
summing O
the O
peak O
intensities O
of O
the O
comprising O
acyl O
anions O
and O
normalized O
against O
the O
acyl O
anion O
signals O
of O
the O
pre-extraction O
spiked O
synthetic O
PE B-lipid
17:0/17:0 I-lipid
standard O
and O
plasma O
volume O
(black O
bars), O
as O
described O
by O
Ejsing O
and O
colleagues. O

In O
addition, O
Pre-DM O
patients O
with O
AO O
had O
significantly O
higher O
levels O
of O
SM36:1, B-lipid
SM38:1 B-lipid
and O
SM40:1 B-lipid
than O
normal O
subjects O
with O
AO. O

(20:4), O
PC B-lipid
(20:1p/19:1), I-lipid
SM B-lipid
(d16:0/22:2), I-lipid
PAF O
(35:4), O
PC B-lipid
(16:0/22:5) I-lipid
and O
PC B-lipid
(18:1/20:4) I-lipid
are O
the O
metabolites O
with O
area O
under O
the O
ROC O
curve O
(AUC) O

Notably, O
the O
LPC B-lipid
(16:1) I-lipid
was O
selected O
for O
time O
points O
2 O
and O
3 O
(Fig. ). O

These O
cutoff O
values O
were O
chosen O
based O
on O
the O
cholesterol O
levels O
in O
children O
and O
adolescents O
developed O
by O
the O
expert O
panel O
of O
the O
National O
Cholesterol B-lipid
Education O
Program O
(NCEP). O

For O
example, O
11,12-EpETrE B-lipid
reduced O
TNFɑ-induced O
VCAM-1 O
surface O
expression O
in O
HAEC. O

Abbreviations: O
DHA, O
docosahexaenoic B-lipid
acid; I-lipid
e, O
ether-linked O
isobaric O
species O
of O
plasmanyl O
analogue O
of O
glycerophospholipids; O
LPC, O
lysophosphatidylcholine; O
SM, O
sphingomyelin; O
TAGs, O
triglycerides. O

The O
branched O
fatty O
acid O
3-methyl-2-oxopentanoic O
acid O
and O
28.6% O
(2/7) O
of O
saturated O
fatty O
acids O
(palmitic O
acid O
and O
stearic O
acid) O
were O
increased, O
while O
71.4% O
(5/7) O
of O
saturated O
fatty O
acids O
(margaric O
acid, O
arachidic O
acid, O
docosapentaenoic B-lipid
acid I-lipid
(DPA), O
10,13-dimethyltetradecanoic B-lipid
acid, I-lipid
propanedioic B-lipid
acid I-lipid
(methyl, O
ethyl O
ester), O
propanedioic B-lipid
acid I-lipid
(methyl, O
ethyl O
ester)) O
were O
decreased. O

No O
statistically O
significant O
differences O
between O
males O
and O
females, O
neither O
for O
the O
AML O
cases O
nor O
the O
controls, O
were O
found O
for O
the O
following O
plasma O
eicosanoids: O
DHGLA O
[20:3(8Z O
,11Z O
,14Z O
)], O
arachidonic O
acid O
[20:4(5Z O
, O
8Z O
,11Z O
,14Z O
)], O
EPA O
[20:5(5Z O
, O
8Z O
,11Z O
,14Z O
,17Z O
)], O
8,9-DHET, B-lipid
11-dehydro-TxB2, O
PGE2/8-isoPGE2, O
12-HEPE, O
11β-PGE2, O
15-keto-PGF2α, O
15-keto-PGE2, O
8-iso-15-keto-PGF2α, O
PGF1α, O
and O
PGF2α. O

Our O
results O
show O
that O
a O
number O
of O
lysophosphatidylcholines O
(LysoPCs) O
are O
obviously O
decreased O
and O
free O
fatty O
acids O
(FFA) O
(linoleic O
acid, O
arachidonic O
acid, O
eicosapentaenoic B-lipid
acid, I-lipid
docosahexaenoic B-lipid
acid, I-lipid
oleic O
acid, O
and O
palmitic O
acid) O
are O
increased O
after O
high-altitude O
exposure O
patients, O
and O
the O
reason O
is O
not O
clear. O

The O
assay O
was O
linear O
at O
low O
(DG O
32:0 O
and O
TG B-lipid
48:0) I-lipid
and O
high O
concentrations O
(DG O
36:3, O
TG B-lipid
54:4) I-lipid
and O
matched O
the O
above O
described O
LoQ O
and O
LoD O
and O
linear O
range O
(up O
to O
250 mg O
DG O
dw/mL O
and O
150 mg O
TG O
dw/mL), O
respectively. O

1: O
aconitic O
acid; O
2: O
adipic O
acid; O
3: O
alanine; O
5: O
arginine; O
6: O
asparagine; O
7: O
aspartic O
acid; O
9: O
citric O
acid; O
12: O
formic O
acid; O
15: O
glutamic O
acid; O
18: O
glycolic O
acid; O
19: O
hippuric O
acid; O
24: O
isocitric O
acid; O
28: O
lactic O
acid; O
33: O
malonic O
acid; O
39: O
propionic B-lipid
acid; I-lipid
40: O
pyroglutamic O
acid; O
43: O
succinic O
acid; O
45: O
threonine; O
46: O
tryptophan. O

Our O
data O
show O
a O
short-term O
increase O
of O
PC38:6 B-lipid
but O
the O
increase O
was O
lower O
at O
the O
long-term O
visit O
relative O
to O
baseline, O
resulting O
in O
a O
Ʌ-pattern. O

We O
also O
measured O
inverse O
relationships O
between O
LPC(20:2) B-lipid
and O
levels O
of O
sCD14 O
and O
TNFR2 O
in O
HIV– O
participant O
serum. O

Two O
LPC’s O
((14:0) O
and O
LPC B-lipid
(16:0)) I-lipid
were O
detected O
with O
both O
platforms O
and O
were O
found O
to O
be O
significantly O
higher O
in O
the O
pre-symptomatic O
individuals O
compared O
with O
controls O
(Figures O
A O
and O
B O
in O
). O

Cholesterol B-lipid
7-desaturase O
is O
a O
critical O
enzyme O
in O
insects O
and O
nematodes O
involved O
in O
the O
synthesis O
of O
steroid O
hormones O
(DAF-36). O

The O
VIP O
plot O
(Figure O
), O
sorted O
by O
importance, O
showed O
the O
metabolites O
tryptophan O
and O
3-hydroxybutanoic B-lipid
acid I-lipid
as O
most O
discriminatory O
between O
GDM O
and O
control. O

Palmitic B-lipid
acid I-lipid
has O
a O
better O
discriminating O
ability O
in O
comparison O
to O
the O
pretherapeutic O
tumor O
marker O
CA O
19-9 O
suggesting O
that, O
the O
joint O
evaluation O
of O
both O
pretherapeutic O
tumor O
markers O
CA19-9 O
and O
palmitic O
acid O
levels O
should O
be O
recommended O
in O
order O
to O
significantly O
reduce O
the O
probability O
to O
detect O
false O
positives O
and O
it O
could O
be O
used O
to O
improve O
the O
prognostic O
prediction O
in O
patients O
with O
pancreatic O
cancer. O

MS/MS O
spectra O
of O
PC B-lipid
16:1/18:2 I-lipid
in O
a O
positive O
ion O
mode O
and O
b O
negative O
ion O
mode. O

lysoPC(16:0) B-lipid
and O
lysoPC(18:0) B-lipid
are O
the O
two O
most O
abundant O
lysophosphatidylcholines O
measured O
in O
plasma. O

N(alpha)-t-Butoxycarbonyl-L-leucine; O
COM530: O
PA(18:4(6Z,9Z,12Z,15Z)/20:4(5Z,8Z,11Z,14Z)); B-lipid
COM548: O
PE(P-16:0/0:0); B-lipid
COM732: O
Val O
Arg O
Phe. O

By O
contrast, O
inverse O
correlations O
(P O
< O
0.05) O
were O
found O
between O
vitamin O
B-12 O
status O
and O
peripheral O
nerve O
function O
with O
uric O
acid, O
trans-4-hydroxyproline, O
sucrose, O
succinic O
acid, O
pyruvic O
acid, O
phenylalanine, O
oxalic O
acid, O
methionine, O
mannitol, O
maltose, O
malic O
acid, O
indole-3-lactate, O
indole-3-acetate, O
glycerol-α-phosphate, O
cysteine, O
citramalic O
acid, O
asparagine, O
arachidonic O
acid, O
2-ketoisocaproic O
acid, O
and O
2-hydroxybutanoic B-lipid
acid. I-lipid

Their O
final O
concentrations O
in O
sample O
extracts O
were; O
1.6 O
μM O
of O
LPC O
17:0, O
PC B-lipid
17:0/17:0, I-lipid
PA B-lipid
17:0/17:0, I-lipid
PE B-lipid
17:0/17:0, I-lipid
PG B-lipid
17:0/17:0, I-lipid
PS B-lipid
17:0/17:0, I-lipid
DAG B-lipid
17:0/17:0, I-lipid
SM B-lipid
18:1/12:0, I-lipid
TAG B-lipid
17:0/17:0/17:0 I-lipid
and O
3.2 O
μM O
of O
D6-CE O
18:0, O
D6-FC O
and O
0.125 O
μM O
of O
SPH B-lipid
17:1 I-lipid
and O
0.5 O
μM O
of O
S1P O
17:1, O
CER O
18:1/17:0, O
D3-GlcCER O
18:1/16:0 O
and O
0.25 O
μM O
of O
D3-LacCER O
18:1/16:0, O
Gb3 O
18:1/17:0. O

In O
addition, O
the O
negative O
association O
between O
lactosylceramide O
and O
PC B-lipid
(18:0/20:4) I-lipid
in O
the O
current O
study O
supports O
previous O
findings O
that O
lactosylceramide O
stimulates O
the O
activity O
of O
cytosolic O
Ca_2+ O
-dependent O
PLA_2 O
, O
of O
which O
the O
preferred O
substrates O
are O
phospholipids O
containing O
arachidonic O
acid O
(20:4 O
ω6) O
at O
the O
sn O
-2 O
site. O

For O
example, O
the O
predicted O
λ O
_b:a O
 O
for O
2-hexenal B-lipid
was O
111, O
therefore O
exchanges O
almost O
exclusively O
in O
the O
airways. O

glycerophosphoserine O
36:1, O
PS B-lipid
(18:1/18:0) I-lipid
(m O
/z O
788.5); O
palmitic O
acid, O
FA B-lipid
(16:0) I-lipid
(m O
/z O
255.3); O
and O
glycerophosphoinositol O
38:4, O
PI B-lipid
(18:0/20:4) I-lipid
(m O
/z O
885.6) O
(SI O
Appendix O
, O
Fig. O

Neither O
of O
the O
recent O
studies O
evaluated O
longitudinal O
diabetes O
incidence O
data; O
however, O
Huynh O
et O
al. O
demonstrated O
a O
significant O
correlation O
between O
1 O
of O
our O
putative O
prognostic O
markers, O
SM B-lipid
d18:1/18:0, I-lipid
and O
fasting O
glucose. O

The O
performance O
of O
the O
FEP O
flow O
microreactor O
for O
the O
PB O
reaction O
was O
evaluated O
using O
model O
lipid O
PC B-lipid
16:0/18:1(9Z) I-lipid
under O
similar O
solvent O
compositions O
as O
used O
in O
HILIC O
separation. O

By O
contrast, O
neutral O
loading O
without O
acidification O
of O
the O
loading O
solution O
greatly O
improved O
recovery O
of O
13-H-9-E-LA O
(86.9 O
to O
107.1% O
across O
concentration O
range) O
and O
achieved O
good O
recoveries O
for O
all O
other O
analytes O
except O
5,6-EET, B-lipid
although O
these O
acidic O
analytes O
would O
likely O
be O
charged O
at O
a O
neutral O
condition. O

HPLC-MS/MS, O
dMRM, O
12-HETE, B-lipid
12-HEPE B-lipid

20-Hydroxyeicosatetraenoic B-lipid
acid, I-lipid
eicosanoids, O
ovarian O
cancer, O
Ras, O
CYP4A/F, O
20-HETE, B-lipid
HRPTEC O
cells O

In O
the O
LC O
group, O
18 O
metabolites O
had O
significantly O
lower O
peak O
intensities O
than O
in O
the O
control O
group; O
glycolic O
acid O
(q O
= O
1.112 O
× O
10_–11 O
), O
myristic O
acid O
(q O
= O
0.019), O
3-hydroxytetradecanedioic B-lipid
acid I-lipid
(q O
= O
0.025), O
α-linolenic O
acid O
(q O
= O
1.877 O
× O
10_–5 O
), O
linoleic O
acid O
(q O
= O
3.805 O
× O
10_–5 O
), O
oleic O
acid O
(q O
= O
0.025), O
9-HOTE B-lipid
(q O
= O
0.001), O
13S-hydroxyoctadecadienoic B-lipid
acid I-lipid
(q O
= O
3.326 O
× O
10_–5 O
), O
9-cis-retinoic O
acid O
(q O
= O
7.158 O
× O
10_–6 O
), O
eicosapentaenoic B-lipid
acid I-lipid
(q O
= O
5.311 O
× O
10_–5 O
), O
5-HEPE B-lipid
(q O
= O
3.021 O
× O
10_–6 O
), O
5-HETE B-lipid
(q O
= O
4.986 O
× O
10_–7 O
), O
leukotriene O
B_4 O
(q O
= O
3.412 O
× O
10_–4 O
), O
17-HdoHE O
(q O
= O
4.587 O
× O
10_–7 O
), O
dehydroepiandrosterone O
sulfate O
(q O
= O
9.100 O
× O
10_–4 O
), O
LPA B-lipid
(16:0) I-lipid
(q O
= O
0.005), O
LPA B-lipid
(18:1) I-lipid
(q O
= O
2.097 O
× O
10_–5 O
), O
and O
PE B-lipid
(P-16:0e) I-lipid
(q O
= O
4.878 O
× O
10_–5 O
). O

Briefly, O
each O
100-ml O
serum O
sample O
was O
mixed O
with O
350 μl O
of O
methanol, O
and O
50 μl O
of O
heptadecanoic B-lipid
acid I-lipid
(dissolved O
in O
methanol O
at O
a O
concentration O
of O
1 mg O
ml_−1 O
) O
was O
added O
as O
an O
internal O
standard. O

Significant O
correlations O
between O
lipid O
levels O
and O
cortical O
gray O
matter O
density. O
LysoPC(18:0) B-lipid
level O
is O
positively O
correlated O
with O
gray O
matter O
density O
mainly O
in O
right O
precentral O
gyrus, O
anterior O
cingulate O
areas, O
and O
medial O
parietal O
and O
occipital O
surfaces. O

All O
of O
the O
11 O
metabolites O
except O
4 O
(3-hydroxybutyrate, O
N-acetyl-glycine, O
3-hydroxy-2-methyl-butanoic B-lipid
acid I-lipid
and O
nonanedioic O
acid) O
have O
been O
identified O
as O
breast O
cancer O
associated O
in O
previous O
studies O
(-). O

 ) O
constructed O
with O
highly O
correlated O
metabolites O
(n = 37), O
it O
was O
evident O
that O
the O
concentration O
levels O
of O
certain O
free O
fatty O
acids O
(FFA) O
such O
as O
arachidonic O
acid O
(AA), O
docosapentaenoic B-lipid
acid I-lipid
(DPA), O
eicosatrienoic B-lipid
acid, I-lipid
docosahexaenoic B-lipid
acid I-lipid
(DHA), O
which O
are O
intermediaries O
of O
linoleic O
acid O
and O
alpha O
linolenic O
acid O
metabolism, O
and O
certain O
lysophospholipids O
such O
as O
lysoPC O
(18:3), O
lysoPC O

The O
area O
under O
the O
curve O
(AUC) O
of O
LysoPC O
[18:2 O
(9Z,12Z)], O
LysoPC O
(P-16:0), O
asparaginyl-proline O
and O
vaccenic O
acid O
in O
the O
comparison O
between O
HCC O
and O
cirrhosis O
were O
all O
increased O
compared O
with O
that O
of O
AFP, O
indicating O
a O
more O
improved O
diagnosis O
ability. O

The O
MS/MS O
spectrum O
of O
FA B-lipid
20:4 I-lipid
is O
shown O
in O
as O
a O
typical O
example O
and O
the O
spectrum O
showed O
characteristic O
product O
ions O
due O
to O
the O
loss O
of O
H_2 O
O O
(18 O
Da) O
and O

Among O
other O
molecular O
ions O
abundant O
in O
BCC O
regions, O
we O
could O
identify O
FA O
dimers O
at O
m O
/z O
537.4 O
(oleic O
acid O
+ O
palmitic O
acid), O
m O
/z O
563.5 O
(oleic O
acid O
+ O
oleic O
acid), O
and O
m O
/z O
585.5 O
(oleic O
acid O
+ O
arachidonic O
acid), O
as O
well O
as O
phospholipids, O
glycerophosphoglycerol O
36:2, O
PG B-lipid
(18:1/18:1) I-lipid
at O
m O
/z O
773.6 O
(SI O
Appendix O
, O
Fig. O

(A) O
[M + H]_+ O
of O
SM16:0. B-lipid

The O
continuous O
line O
represents O
urine O
sphingosine O
and O
the O
dashed O
line O
represents O
serum O
S1P. O
We O
also O
examined O
the O
correlation O
between O
the O
SL O
metabolites O
at O
the O
basal O
status O
and O
15-HETE B-lipid
which O
has O
been O
known O
to O
be O
as O
a O
diagnostic O
biomarker O
for O
AERD. O

As O
a O
consequence, O
the O
synthesis O
of O
lipids O
downstream O
of O
this O
enzyme O
such O
as O
the O
eicosanoid O
precursors O
(arachidonic O
acid O
(C20:4n-6), O
eicosapentaenoic B-lipid
acid I-lipid
(C20:5n-3) O
and O
docosahexaenoic B-lipid
acid I-lipid
(C22:6n-3)) O
exhibited O
a O
significant O
decrease O
in O
livers O
of O
NASH O
compared O
to O
controls. O

While O
these O
higher O
amounts O
were O
most O
notable O
for O
15-HETE B-lipid
and O
17-HDHA, O
even O
these O
differences O
were O
not O
significant. O

While O
some O
of O
these O
metabolites O
have O
been O
reported O
previously, O
recent O
work O
by O
Wang O
et O
al. O
has O
shown O
the O
discovery O
of O
down-regulation O
of O
GCDCA O
and O
its O
fragments O
(m/z O
414.3) O
in O
serum O
of O
patients O
with O
HCC, O
and O
up-regulations O
of O
LPC B-lipid
(16:0), I-lipid
LPC B-lipid
(18:0) I-lipid
and O
other O
PCs, O
supporting O
our O
previous O
interpretation. O

The O
prohypertensive O
effects O
of O
either O
increased O
or O
decreased O
renal O
20-HETE B-lipid
production O
depends O
on O
the O
principal O
site, O
either O
a O
nephron O
segment O
such O
as O
the O
TAL O
(decreased O
20-HETE) O
or O
renal O
microvessels O
(increased O
20-HETE) O
as O
the O
afferent O
arteriole, O
that O
exhibits O
altered O
synthesis O
of O
20-HETE. B-lipid

Highest O
mean O
concentrations O
were O
detected O
for O
polyunsaturated O
species O
with O
more O
than O
two O
double O
bonds: O
DG B-lipid
36:3, I-lipid
DG B-lipid
36:4, I-lipid
TG B-lipid
54:3, I-lipid
TG B-lipid
54:4, I-lipid
and O
TG B-lipid
54:5. I-lipid

Cholesterol B-lipid
levels O
changed O
very O
little O
with O
treatment O
(1.06 O
fold O
change, O
P O
= O
0.029). O

Palmitic B-lipid
acid I-lipid
or O
hexadecanoic B-lipid
acid I-lipid
is O
one O
of O
the O
most O
common O
saturated O
fatty O
acids O
found O
in O
animals, O
a O
saturated O
fatty O
acid O
found O
in O
fats, O
waxes O
and O
body O
lipids. O

This O
fits O
with O
the O
fact O
that O
ABCD2 O
and O
LAA O
are O
closely O
related O
to O
pathophysiologic O
events O
previously O
invoked O
in O
the O
homeostasis O
of O
LysoPC16:0 B-lipid
(enumerated O
above). O

Given O
this, O
good O
quantitation O
of O
17-HDoHE B-lipid
would O
not O
be O
possible O
if O
there O
was O
not O
enough O
LC O
resolving O
power. O

All O
the O
metabolites O
measured O
in O
this O
study O
were O
detected O
in O
all O
608 O
serum O
samples O
except O
LPI B-lipid
(22:6), I-lipid
which O
was O
detected O
in O
92.4% O
of O
all O
samples. O

Interestingly, O
Lemaitre O
et O
al. O
reported O
a O
complex O
relationship O
between O
several O
SMs O
(including O
SM B-lipid
d18:1/18:0) I-lipid
and O
insulin O
sensitivity O
that O
was O
dependent O
upon O
BMI. O

Our O
findings O
on O
the O
increased O
concentration O
of O
8,9-EpETrE, B-lipid
suggesting O
increased O
activity O
of O
CYP O
enzyme, O
would O
support O
promotion O
of O
cellular O
detoxification O
mechanisms O
through O
specific O
modulation O
of O
the O
arachidonic O
acid O
metabolic O
cascade O
in O
centenarians. O

For O
example, O
there O
can O
be O
multiple O
isobaric O
lipid O
species O
under O
one O
chromatographic O
peak, O
for O
example O
TG B-lipid
(48:0) I-lipid
may O
consist O
of O
TG B-lipid
(16:0/16:0/16:0), I-lipid
TG B-lipid
(18:0/16:0/14:0), I-lipid
TG(18:0/14:0/16:0) B-lipid
and O
TG(14:0/18:0/16:0), B-lipid
depending O
on O
the O
acyl O
chains. O

Six O
lipids, O
DG B-lipid
(36:4), I-lipid
TG B-lipid
(56:2), I-lipid
TG B-lipid
(54:1), I-lipid
TG B-lipid
(49:1), I-lipid
TG B-lipid
(51:1) I-lipid
and O
TG B-lipid
(56:3), I-lipid
were O
identified O
as O
potential O
biomarker O
candidates O
to O
discriminate O
saline O
and O
meloxicam-treated O
cats. O

This O
is O
in O
line O
with O
past O
literature O
reporting O
an O
increase O
in O
decanoic B-lipid
acid I-lipid
42 days O
after O
RYGB.31 O
Decanoic B-lipid
acid I-lipid
is O
a O
medium O
chain O
FA O
(MCFA). O

Cholesterol, B-lipid
LDL, O
grip O
strength, O
lysoPCs O
(16:0, O
17:0, O
18:0, O
18:1 O
(11Z), O
18:3(9Z, O
12Z, O
15Z), O
P-18:1 O
(9Z), O
20:1 O
(11Z), O
(20:3 O
(8Z, O
11Z, O
14Z)), O
glycerophosphocholine, O
ornithine, O
glucuronic O
acid, O
glycerophosphoserine O
and O
taurocholic O
acid O
were O
sensitive O
markers O
in O
the O
assessment O
of O
nutritional O
status. O

 528.6; O
and O
PC B-lipid
(40:2) I-lipid
at O
m/z O
= O
842.90. O

In O
the O
patient O
group O
with O
highly O
active O
MS, O
15-HETE B-lipid
and O
PGE_2 O
were O
increased, O
which O
are O
products O
of O
the O
15-lipoxygenase O
and O
cyclooxygenase O
pathways. O

Based O
on O
this O
pattern O
we O
could O
identify O
two O
PC's, O
PC(40:6) B-lipid
and O
PC(40:7), B-lipid
which O
were O
specifically O
increased O
in O
plasma O
following O
dietary O
TFAs, O
and O
PC(38:4), B-lipid
which O
tended O
to O
be O
increased O
as O
well. O

4-Hydroxynonenal B-lipid
(HNE) O
was O
measured O
using O
OxiSelectTM O
HNE O
Adduct O
Competitive O
ELISA O
Kit O
(Cell O
Biolabs, O
Inc., O
San O
Diego, O
CA) O
following O
the O
manufacturer’s O
protocol. O

The O
metabolites O
were O
ChoE(18:1), O
ChoE(18:2), O
ChoE(20:4), O
PE(16:0/18:1), B-lipid
SM(d18:1/23:0), B-lipid
SM(42:3) B-lipid
and O
TG(54:1) B-lipid
and O
the O
model O
was: O

Compared O
with O
those O
in O
HC, O
significant O
increases O
in O
the O
levels O
of O
saturated O
and O
monounsaturated O
PCs O
such O
as O
PC B-lipid
(15:0/18:1), I-lipid
PC B-lipid
(18:0/16:0) I-lipid
and O
PC B-lipid
(18:0/20:1) I-lipid
were O
observed O
in O
NSCLC. O

These O
7 O
metabolites O
were O
acetone, O
2-butanone, O
4-heptanone, O
dimethyl O
disulfide, O
furan, O
2-methylbutanal B-lipid
and O
2-methylpyrazine. O

A O
stable O
20-HETE B-lipid
agonist O
induced O
activation O
of O
the O
small-GTPase O
Ras O
in O
HRPTEC O
cells. O

Alterations O
in O
levels O
of O
CYP O
enzymes, O
20-HETE B-lipid
or O
EETs O
contribute O
to O
endothelial O
dysfunction O
and O
cardiovascular O
diseases O
such O
as O
ischemic O
injury, O
hypertension O
and O
atherosclerosis O
[,]. O

Low O
(DG O
32:0, O
TG B-lipid
48:0), I-lipid
medium O
(DG O
34:2, O
TG B-lipid
52:2), I-lipid
and O
high O
(DG O
36:3, O
TG B-lipid
54:4) I-lipid
abundant O
species O
showed O
a O
good O
correlation O
of O
expected O
and O
measured O
concentrations O
(ESM O
Fig. O

Previous O
studies O
determined O
the O
positive O
relationship O
among O
lower O
9-HODE B-lipid
concentrations O
and O
Mediterranean O
diet O
to O
reduced O
cardiovascular O
disease O
risk O
, O
and O
our O
results O
might O
underpin O
this O
trend, O
while O
at O
the O
same O
time O
revealing O
decreased O
oxidative O
damage O
in O
centenarians. O

New O
SM O
molecules O
were O
most O
probably O
generated O
from O
degraded O
PC O
compounds O
by O
SM O
synthase O
(this O
transferase O
utilizes O
a O
choline O
“head” O
from O
PC) O
and O
suitable O
ceramide O
molecules, O
which O
was O
coherent O
with O
observed O
down-regulation O
of O
Cer(36:2). B-lipid

Although O
matrix O
effect O
was O
observed O
for O
Cer(22:0) B-lipid
in O
plasma, O
the O
co-elution O
of O
deuterium-labeled O
internal O
standard O
compensated O
the O
matrix O
effect O
and O
the O
accuracy O
and O
precision O
were O
not O
affected. O

